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Multiple Endocrine Neoplasia type 1 (MEN1) is a hereditary cancer syndrome
characterized by tumors of the endocrine system. Tumors most commonly develop in the
parathyroid glands, pituitary gland, and the gastro-entero pancreatic tract. MEN1 is a highly
penetrant condition and age of onset is variable. Most patients are diagnosed in early
adulthood; however, rare cases of MEN1 present in early childhood. Expert consensus opinion
is that predictive genetic testing should be offered at age 5 years, however there are no
evidence-based studies that clearly establish that predictive genetic testing at this age would be
beneficial since most symptoms do not present until later in life. This study was designed to
explore attitudes about the most appropriate age for predictive genetic testing from individuals
at risk of having a child with MEN1. Participants who had an MEN1 mutation were invited to
complete a survey and were asked to invite their spouses to participate as well. The survey
included several validated measures designed to assess participants’ attitudes about predictive
testing in minors. Fifty-eight affected participants and twenty-two spouses/partners completed
the survey. Most participants felt that MEN1 genetic testing was appropriate in healthy
minors. Younger age and increased knowledge of MEN1 genetics and inheritance predicted
genetic testing at a younger age. Additionally, participants who saw more positive than
negative general outcomes from genetic testing were more likely to favor genetic testing at
younger ages. Overall, participants felt genetic testing should be offered at a younger age than
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most adult onset conditions and most felt the appropriate time for testing was when a child
could understand and participate in the testing process. Psychological concerns seemed to be
the primary focus of participants who favored later ages for genetic testing, while medical
benefits were more commonly cited for younger age. This exploratory study has implications
for counseling patients whose children are at risk of developing MEN1 and illustrates issues
that are important to patients and their spouses when considering testing in children.
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Multiple Endocrine Neoplasia, type 1
Multiple Endocrine Neoplasia type 1 (MEN1) is a hereditary cancer syndrome
characterized by tumors of the endocrine system. The most commonly associated tumors are
those of the parathyroid glands, endocrine cells of the gastro-entero-pancreatic tract and the
anterior pituitary gland. A clinical diagnosis of MEN1 can be made when a patient presents
with two of these three classic tumor types or one of these tumors and a family history of
MEN1 [1]. The majority of MEN1 tumors are not malignant. However, damaging effects can
be seen from the continuous overproduction of hormones or the size and location of tumors [2].
MEN1 is inherited in an autosomal dominant manner meaning that each child of an affected
person has a 50% risk of inheriting this condition. It is a rare syndrome with an estimated
prevalence of 1 in 30,000 [3]. MEN1 appears to have no predilection for any ethnic group and
has been seen across many different populations. Improvements in screening and diagnostic
measures have greatly improved the detection rate of MEN1-related tumors in recent years,
which has resulted in more successful interventions and decreased mortality.
Parathyroid Tumors
Parathyroid tumors are the most common manifestation of MEN1 and have a lifetime
prevalence of 90-99% [4] [5] [6] [7]. Both hyperplasia and adenomas can be found in the
parathyroids of MEN1 patients. Often these are multiple, asymmetric tumors that may involve
three or four of the parathyroid glands [1]. Parathyroid tumors create excessive secretion of
parathyroid hormone (PTH) leading to elevated serum calcium levels, which is a condition
known as primary hyperparathyroidism (PHPT). PHPT is the first presenting sign in 40-90%
of MEN1 patients [8] [9] [10] [11]. PHPT is not uncommon in the general population and is
more common in females than males when sporadic [12]. Overall, MEN1 accounts for 4-5% of
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PHPT patients [13]. Distinguishing features of PHPT that are suggestive of an MEN1
diagnosis are a young age of onset, males affected with PHPT, parathyroid hyperplasia rather
than an adenoma, lower parathyroid hormone levels than sporadic, more severe bone
involvement, and multigland involvement [1] [12] [14]. Although tumors of the parathyroid
are rarely malignant, the chronic over-expression of parathyroid hormone can have lasting and
damaging effects. Most notable, extended PHPT can lead to renal stones, nephrocalcinosis and
renal failure. It can also lead to skeletal problems including osteoporosis usually in the fourth
decade of life [14] [15] [16].
Treatment for parathyroid tumors is somewhat controversial, although surgery is the
preferred management of PHPT in MEN1 patients. Indications for a parathyroidectomy in
MEN1 do not differ significantly from those with sporadic PHPT. In 1990, the NIH published
a consensus statement addressing indications for surgery in patients with PHPT which included
strongly elevated levels of serum calcium and resulting effects of hypercalcemia, lower
creatinine clearance levels, and significantly decreased bone mass [17]. Timing of surgery has
also been questioned, mainly because the long-term effects of PHPT are unknown [1] [17].
This is particularly relevant to patients with MEN1, who are diagnosed with PHPT on average
30 years younger than sporadic PHPT [1].
The overall goal of surgical intervention for parathyroid tumors in MEN1 is to reduce
disease persistence and recurrence. The multigland involvement and asymmetrical presentation
of parathyroid glands can make surgical intervention more complicated in patients with MEN1
and it is still debated whether a subtotal parathyroidectomy or a total parathyroidectomy with
autotransplantation is more effective. A subtotal parathyroidectomy involves the removal of 3
to 3.5 parathyroid glands. A total parathyroidectomy with autotransplantation involves the
removal of all four parathyroid glands and autotransplantation of parathyroid tissue elsewhere
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in the body, usually to the forearm. With either surgery, there is a strong concern for
hypoparathyroidism, which causes low serum calcium levels affecting the nervous system,
skeletal muscles, and cardiac system [18]. In roughly half of patients, permanent
hypoparathyroidism can be corrected with autotransplantation emphasizing the importance of
cryopreservation with either procedure [19]. Both procedures are considered acceptable
treatment options by the National Comprehensive Cancer Network guidelines [20]. Unlike
other endocrine tumor conditions, such as Multiple Endocrine Neoplasia type 2, prophylactic
surgery is not generally recommended.
Gastro-entero-pancreatic tumors
Gastro-entero-pancreatic tumors are the second most common tumor type in patients
with MEN1 and are found in up to 80% of patients [1] [21] [22]. Unlike most other MEN1
associated tumors, gastro-enteropancreatic tumors have a high risk of malignancy, with the
exception of insulinomas. These neuroendocrine tumors are the most common cause of
MEN1-related death accounting for two-thirds of young deaths [23]. The most common of
these tumors are gastrinomas, which make up for roughly 40% of MEN1-related
neuroendocrine tumors [1]. Gastrinomas lead to elevated gastrin levels and can eventually lead
to Zollinger-Ellison Syndrome (ZES), a condition that presents with gastrointestinal
complications including abdominal pain, diarrhea, heartburn, weight loss and gastrointestinal
bleeding [24] Twenty to twenty-five percent of all patients with Zollinger Ellison Syndrome
have MEN1 [25]. Patients with MEN1 can have gastrinomas in the pancreas, but most often
they originate in the duodenum [26]. Both locations carry a risk of malignancy. MEN1-related
gastrinomas are usually small and multifocal making them difficult to detect radiographically
[26]. About 50% of patients with a gastrinoma have already had metastasis at diagnosis [1].
Surgical intervention for gastrinomas in MEN1 patients is highly controversial. Some advocate

3

a nonsurgical management option usually involving the use of a proton pump inhibitor to
reduce gastric acid production. Others support a more aggressive, surgical approach when the
tumor reaches 3 cm to prevent further metastasis [1] [27] [28].
The second most common neuroendocrine tumor, accounting for 10-12%, is an
insulinoma [1] [5]. MEN1- related insulinomas are usually benign [29]. Medical management
for insulinomas is less effective than surgery and therefore, surgery is the preferred treatment.
A total pancreatectomy carries a high rate of morbidity and mortality and is therefore not
recommended [2] [30]. However, a distal pancreatectomy with enucleation has been shown to
have a very high cure rate with a low risk of recurrent disease [31]. Tumors found in the head
of the pancreas should also be treated with partial pancreatectomy [14,31]. More aggressive
surgical resection is recommended for MEN1-related insulinomas due to the possibility of
multiple, small insulinomas throughout the pancreas [25].
Other hormone-producing neuroendocrine tumors include glucagonoma, vasoactive
intestinal peptide (VIP) and somatostatinoma. These tumors are rare but can occur in up to 5%
of patients with MEN1 [1] [5] [28]. Additionally, up to 36% of patients with pancreatic
endocrine tumors have a non-hormone secreting tumor that may have no clinical implications
except for the size, mass-effect, and malignant potential [32].
Pituitary tumors
Tumors of the anterior pituitary affect 20 to 65% of MEN1 patients [8] [11] [15] [33].
Pituitary tumors are the first presenting manifestation in roughly 17% of MEN1 patients [8]
[33]. These tumors can be either non-functioning in 11 to 38% [5] [33] [6] or hormone
secreting. The most common type of MEN1-related pituitary tumor is a prolactinoma. Other
hormone secreting pituitary tumors include growth-hormone-secreting (5-10%), which can
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cause acromegaly, and ACTH-secreting (2-5%), which can cause Cushing’s disease [1] [28]
[30]. Most tumors are macroadenomas and can have severe mass effects, although most are not
malignant [33]. Pituitary tumors are rarely the only MEN1-related tumor seen in a patient and,
therefore, often serve as the second tumor in a clinical diagnosis [33]. An isolated pituitary
tumor is not highly suggestive of MEN1 as pituitary lesions have been seen with MRI in 16%
of the general population [34]. MEN1 is thought to be responsible for only 2.7% of isolated
pituitary adenomas [21].
Treatment for pituitary tumors in patients with MEN1 is identical to treatment for
patients with sporadic pituitary tumors. This treatment includes surgery, medical management,
and/or radiation [14][28]. However, success rates do not seem to be as high in patients with
MEN1 as it is in patients with sporadic tumors [33] and continued screening is recommended to
avoid a recurrence [1].
Other MEN1-associated tumors
Other tumors have been associated with MEN1 less commonly than the three main
tumor types. Five to ten percent of patients are diagnosed with a foregut carcinoid. Of these,
bronchial and gastric carcinoids are less likely to be malignant while thymic carcinoids can be
aggressive and are a major cause of mortality among MEN1 patients [4][35]. Often, a subtotal
or total parathyroidectomy to treat a parathyroid tumor will include removal of the thymus to
avoid potential future thymic carcinoids. Adrenocortical tumors and benign thyroid tumors
may also be caused by mutations in the MEN1 gene. Some association has been seen with
renal angiomyolipoma, and leiomyomas of the esophagus [5]. Collagenomas are seen in up to
72% of patients and lipomas are seen in roughly 34% [36] [37]. Several rare skin findings have
also been associated with MEN1. Multiple facial angiofibromas are seen in 20 to 88% of
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patients with MEN1 [36] [37]. Given the rarity of angiofibromas in the general population,
MEN1 should be a highly considered differential diagnosis in their presence.
Age of Diagnosis
MEN1 is a highly penetrant condition with 90-100% of patients exhibiting clinical
manifestations by age 60 years [4] [8] [38]. A few reports of patients diagnosed before age 10
years have been published, although this is rare. These include a five-year old diagnosed with a
pituitary macroadenoma [39], and two eight-year olds diagnosed with an insulinoma [40] [41].
Despite rare reports of children younger than ten being diagnosed with symptoms of MEN1,
the overall penetrance is reported to be only 7% for this age group [38]. Penetrance increases
to 52% by age 20 and reaches 98% by age 40 [38]. Studies investigating penetrance and age of
onset have all been retrospective but have generally found the average age of diagnosis to be in
early adulthood [4] [8]. Specifically, primary hyperparathyroidism was diagnosed on average
by age 37 years, pituitary tumors by age 40 years, and GI endocrine tumors by age 46 years [8].
However, the wide range of ages observed for the diagnosis of each tumor type emphasizes the
extreme variability in age of diagnosis. The average age of death related to MEN1 appears to
be around age 50 years most commonly due to neuroendocrine tumors [8] [23]. It has been
noted that there is a higher rate of diagnoses at young ages within the past decade, which is
likely attributable to improved screening [35]. Males and females are affected in equal
numbers, although recent data suggests a slight difference in phenotype, with men having a
higher prevalence of pancreatic and thymic tumors while women have a higher prevalence of
pituitary tumors. There appears to be no differences between genders in the rate of
hyperparathyroidism or positive genetic tests [42].
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Screening
Over the past few decades, screening methods have drastically improved resulting in
earlier intervention and decreased morbidity. In 2001, an international group of clinical
endocrinologists published a set of guidelines for diagnosis, treatment and screening of MEN1
[1]. Since its publication, this has been widely accepted as the consensus protocol, although
additional groups have published other guidelines that only slightly differ in age and frequency
of screening [30]. Because most endocrine tumors are functional, biochemical screening has
proven to be an effective modality. Additionally, imaging techniques are often able to detect
smaller lesions and non-functioning pituitary and pancreatic neuroendocrine tumors. In
general, biochemical testing is recommended on an annual basis while imaging studies are
generally recommended every 1 to 3 years or when biochemical tests are abnormal.
For parathyroid tumors, screening of calcium and parathyroid hormone levels has been
recommended as early as age 8 years, although others have suggested postponing screening
initiation until age 20 years, which is closer to the average age of onset for primary
hyperparathyroidism [1] [30]. These levels can also be used to test post-operative success and
monitor for signs of recurrent disease following surgery.
Screening for functional pancreoenteric tumors can be done by evaluating their
respective biochemical markers following a fasting period. Because insulinomas have been
identified in patients at a particularly young age, screening is recommended beginning at age 5,
whereas screening for gastrinomas can be delayed until age 20 years [1]. Regular imaging,
including computed tomography (CT) scan and magnetic resonance imaging (MRI), are
recommended to detect non-functional pancreoenteric tumors which may not be found through
routine biochemical screening [1] [7].
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Screening for pituitary disease is recommended beginning at age 5 [1] due to a reported
pituitary macroadenoma in a 5-year-old patient [39]. Laboratory tests include monitoring
prolactin and insulin-like growth factor 1 (IGF-1) [1] [30]. MRI of the pituitary is
recommended every 3 years, regardless of biochemical results. Screening should continue after
surgical treatment due to the lower curative success rates in MEN1 patients compared with
those who have sporadic pituitary disease [33].
Many of the less commonly associated tumors do not hypersecrete hormones: therefore,
screening guidelines tend to focus on imaging techniques rather than biochemical analysis. The
main recommendation for the detection of carcinoid tumors is a CT scan or MRI every 3 years
beginning at age 20 [1].
Consensus guidelines tend to recommend screening at a younger age than the average
age of onset because of a few reported MEN1 diagnoses before 10 years of age. However,
several authors have suggested that these recommendations are unnecessarily aggressive. A few
have stated that biochemical screening can be postponed until 15 years for pituitary tumors and
20 years for all other types of tumors, with imaging being performed every three years or only
if biochemical tests are abnormal [30]. Guidelines have been difficult to establish given the
debate surrounding implications of an abnormal test result. The penetrance of biochemical
signs in asymptomatic patients is up to 43% by age 20 years, more than twice the penetrance of
MEN1 disease in symptomatic patients [11]. Similarly, it has been suggested that the low
penetrance among younger age groups may be an underestimate and that asymptomatic
children may actually have non-functioning neuroendocrine tumors [43]. The nature of these
tumors in particular can be difficult to predict and surgery at a young age can have its own
complications.
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Studies have shown that genetic testing has allowed for earlier screening and can detect
biochemical changes 10 years prior to the development of disease symptoms [2]. However,
timing for surgical intervention is debated and often delayed until a child begins to show
symptoms regardless of prior biochemical or radiographic findings [1]. The NIH consensus
statement on primary hyperparathyroidism in adults recommends medical monitoring for
asymptomatic patients with biochemical evidence of primary hyperparathyroidism and has
specific criteria before beginning surgical intervention [17]. Guidelines are less clear for an
appropriate time for intervention in children. This has raised the question of the benefits of
presymptomatic screening, which poses potential risks for increased stress and anxiety in
children and their parents, before any treatment would be indicated.
Molecular Genetics of MEN1
In 1997, mutations in the MEN1 gene on chromosome 11q13 were found to be
associated with the clinical diagnostic criteria for multiple endocrine neoplasia type 1. MEN1
is comprised of 10 exons, which code for the 610 amino acid protein, menin [44]. This protein
has been shown to play a role in DNA replication and repair, transcriptional regulation, cell
division and proliferation [3]. MEN1 is suspected to have a tumor suppressor role that follows
Knudson’s “two-hit” model as the majority of tumor cells show loss of heterozygosity [45].
This theory matches an autosomal dominant inheritance whereby a germline mutation in one
allele accounts for the first “hit”, and the second is due to a somatic mutation that then leads to
tumor initiation and growth [46].
Over 450 germline mutations have been identified in the MEN1 gene. Most mutations
are frameshift insertions or deletions (41%) followed by nonsense mutations (23%), missense
mutations (20%), splice site mutations (9%), in-frame deletions and insertions (6%) and large
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deletions (1%) [47]. Mutations have been found throughout the coding regions and non-coding
regions and no genotype-phenotype correlations have been identified. Sequencing is
commercially available and is the most effective method of genetic testing. The detection rate
for an MEN1 mutation in people who meet a clinical diagnosis of MEN1 is about 65% for
patients with a non-familial presentation [48] and up to 90% in patients meeting a familial
MEN1 clinical diagnosis [28]. Additionally, 4% of mutations are large deletions that can be
detected using multiplex ligand-dependent probe amplification (MLPA) [49]. In the event of a
negative results, an MEN1 diagnosis cannot be ruled out, particularly for patients who meet
clinical diagnostic criteria [28]. Medical management for these patients is the same as those
with an identified mutation. Approximately 10% of patients have a de novo mutation [38].
Genetic Testing in Minors
Over the past several decades, genetic testing has become more widely available for
numerous genetic conditions and access to testing is improving. Genetic testing is frequently
used for symptomatic patients as a diagnostic tool to confirm a suspected genetic condition.
Establishing a genetic diagnosis can direct personalized medical care because it provides
patients and physicians with information regarding natural history and prognosis. In oncology,
genetic testing has been used for many cancer syndromes to provide information regarding
risks for second primary cancers or responses to various treatments. For symptomatic
individuals, this diagnostic advancement has clearly demonstrated benefits in helping to
diagnose and understand disease.
Genetic testing can also serve as a powerful predictive tool for the asymptomatic
individual. Many hereditary cancer syndromes have prophylactic treatment options or
increased surveillance methods. For many conditions, predictive genetic testing can also help
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individuals anticipate and psychologically plan for a medical condition they may someday face.
However, there are potential psychological risks associated with predictive testing in an
asymptomatic individual; therefore, the appropriate age for predictive genetic testing for adult
onset conditions is typically considered as the age of consent, and testing in minors is highly
debated.
Professional Guidelines
Conditions for which genetic testing is available can be divided into three main groups
with regards to the impact on minors: conditions for which there is an immediate medical
benefit, conditions for which any medical benefit would be delayed until adulthood, and
conditions where there is no known medical intervention that would affect disease severity.
Several professional organizations have issued position statements regarding genetic testing in
minors. In 1995, the American College of Medical Genetics (ACMG) and the American
Society of Human Genetics (ASHG) issued a joint position statement acknowledging the
importance of balancing medical and psychological benefits, family structure, and the decisionmaking capabilities of the minor [50]. The statement asserts that genetic testing in minors is
justified when an immediate medical or considerable psychological benefit exists. When
medical and psychosocial benefits would be deferred until adulthood, genetic testing should
also be deferred until the patient is no longer considered a minor. For conditions in which the
benefits and harms are unclear, decisions about genetic testing should be left up to the family
and competent adolescents.
The American Medical Association (AMA) issued a similar set of recommendations in
1995 adding that genetic testing should be encouraged, if not required, if therapeutic measures
are available [51]. The recommendations also noted the importance of making parents aware
of genetic testing for adult onset conditions so they may inform their children of its availability.
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The recommendations considered the possibility of testing for the benefit of other family
members, and indicate that such testing should only be undertaken if not doing so would
provide considerable harm to the at-risk family member.
Clinical manifestations of MEN1 are complex and thus interpretation of general testing
guidelines for minors is not as straightforward compared with other syndromes. Most persons
with MEN1 are not diagnosed with a syndrome-related tumor until young adulthood. Although
some persons will begin to show signs of hyperparathyroidism in adolescence, surgical
intervention may not necessarily take place during childhood. For most patients with MEN1, it
is unclear if there is a direct medical benefit to testing before adulthood. However, rare reports
exist of clinically diagnosed MEN1 in patients under the age of ten, suggesting that there may
be a rare medical benefit [39] [41]. For this reason, most guidelines suggest beginning
screening at age 5. However, these guidelines rarely take into account any potential
psychological sequelae for both children and parents associated with frequent screening at a
young age for a condition that often does not present until later in life.
Given the potential for a significant psychological impact of predictive testing on
healthy minors, several authors have looked at the potential effects on minors and their
families. Childhood and adolescence are marked by changing opinions and developing thought
processes. As they are growing, children begin to form an individualized image that can be
greatly shaped by outside events in their lives. It has been suggested that results of predictive
genetic testing in minors, particularly positive results, may interfere with development of a selfconcept and cause children to identify themselves by the disease they have inherited but are not
yet exhibiting [52]. Particularly at young ages, many children may perceive disease and illness
as a sort of punishment [53] which may influence their developing self-image. On the other
hand, it has been suggested that providing genetic risk information to children at a young age
could facilitate children’s adjustment to their carrier status earlier as opposed to the jarring
12

experience of learning it later in life and perhaps not being given the opportunity to incorporate
this information into their life plans [54].
As children continue to develop their self-image and self-concept, predictive genetic
testing may potentially impact not only the child but also family and sibling relationships.
Stigmatization is an important consideration for persons who receive mutation positive
predictive genetic testing results. Examples include lowered expectations of mutation positive
persons within a family or feelings of unworthiness [53]. Children who have inherited a genetic
mutation associated with a hereditary condition may be impacted as parents struggle with ways
to express their own guilt about having passed on this genetic condition. Additionally, several
authors have pointed to the idea of “vulnerable child syndrome,” where parents are
overprotective of children who they perceive to be at risk of an early death because of an illness
or previous close call [53] [55] [56]. Sibling relationships also may be strained when a child
tests positive for a genetic condition, particularly if the other child tested negative. This can
occasionally lead to feelings of survivor’s guilt in the unaffected child [53].
A commonly cited reason for genetic testing in minors is to reduce the anxiety of the
parents who perceive that the burden of uncertainty is greater than the knowledge of what lies
ahead. However, justifying predictive genetic testing for adult onset conditions in
asymptomatic children for the benefit of the parents may be viewed as a direct challenge to the
child’s autonomy [52]. In most legal systems, parents have the right to make medical
decisions for their children until they reach the age of legal adulthood (usually 18 years) or
until the child has become an emancipated minor. However, it has been advocated that most
children may be able to understand, to some degree, the implications of their medical care and
as such, should have an adequate say in the type of medical treatment they receive [53] [57].
Therefore, there is often a requirement to have a child assent to a procedure or test before they
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have acquired the ability to fully consent [53]. This often begins when children reach age 7
while acknowledging that children have varying rates of development and maturity [50] [53].
It is assumed that a child competent of assenting is capable of understanding a medical
procedure and is able to agree or disagree with a parent’s decision. The principles of informed
consent takes this understanding a step further whereby an individual is not only able to explain
the procedure and testing that will take place, but also exhibits a voluntary desire to have the
testing, a clear understanding of the risks, benefits, and alternative options, and recognition of
the direct and indirect impacts a test can have on the individual, family members or others [52]
[53]. It is difficult to state at what age a person is capable of providing adequate informed
consent given the differing rates of maturity. However, in most legal systems the age of 18 has
been established as a point at which most individuals can make comprehensive decisions about
their own health, medical care, and personal rights.
Upholding a child’s future autonomy is important in maintaining their ability to make
independent decisions for their own life plan and health care management. Genetic testing
affords the ability to predict an outcome that previously would have been left unknown until
the development of disease. But with advances in genetics, patients have had to balance their
rights to know their medical future with their rights not to know what lies ahead [57]. In fact,
since the discovery of the HD gene responsible for Huntington disease, the uptake of genetic
testing has only been between 5-20% [58]; albeit there are no medical interventions available to
reduce the burden of Huntington disease. Among the most commonly cited reasons for
declining genetic testing for Huntington disease has been a lack of cure and, therefore, the
emotional pain of knowing the inevitable outcome is greater than the burden of not knowing
[59]. Parental decisions to initiate genetic testing in asymptomatic minors deny them their
ability to weigh these pros and cons and take away their right to decline testing.
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Parental Opinions
Balancing the perceived risks of predictive genetic testing in minors with the desires of
parents to do what they believe is in the best interest of their child and their family can be
difficult, especially when parents are the ones affected. Several studies have investigated
parental opinions regarding predictive genetic testing for various conditions. Familial
adenomatous polyposis (FAP) is a hereditary cancer syndrome characterized by hundreds of
colon polyps and a very high risk for colon cancer if left untreated. Parents of children at risk
of inheriting FAP have cited seeking out increased surveillance measures and prophylactic
options as reasons for supporting genetic testing in children [60]. Screening recommendations
for FAP include initiating annual colonoscopies beginning at age ten, since the average age of
onset of colon polyps is around 16 years [61]. Therefore, a second commonly cited reason for
genetic testing is to prevent unnecessary screening in children who test negative. Other reasons
parents have cited for genetic testing include reducing anxiety and increasing knowledge [59]
[60] [62].
In contrast to FAP, parents of children at risk of developing hereditary breast and
ovarian cancer generally support postponing genetic testing until adulthood. Hereditary breast
and ovarian cancer is characterized by up to an 87% lifetime risk of breast cancer and up to a
44% risk of ovarian cancer [63]. Screening is usually recommended beginning at age 25 or at 5
to 10 years earlier than the youngest age of diagnosis in the family. A study of BRCA mutation
carriers by Bradbury et al. [64] found that 55% were completely opposed to genetic testing in
minors with the most commonly cited reasons being that there is no medical indication for
testing (46%), that it would cause fear and anxiety (46%), and that minors are not mature
enough for the information (46%). Twenty-four percent indicated that genetic testing should
only be considered in minors under specific circumstances with the most common situations
being that the child is exceptionally mature (39%) and there is a potential medical risk that
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could be mitigated by knowing the result of the genetic test (33%). The overall consensus
among parents who are BRCA1/2-mutation carriers is that due to the later age of onset for
HBOC, genetic testing in most circumstances should be deferred until adulthood when children
are mature enough to make their own decisions.
Borry et al. [65] reviewed 14 sets of guidelines from 24 professional organizations
about carrier testing (i.e. testing for information on reproductive risk rather than personal
medical risk) in minors and found that the majority of guidelines endorsed not performing
carrier testing in children but rather deferring testing until a time when children can give
adequate informed consent. Although many guidelines established a critical difference
between childhood and adolescence in regard to the ability to provide adequate informed
consent, few established an exact age at which a child should make their own decisions about
testing and stated that it depended on the maturity of the child. However, many guidelines and
authors have pointed out that carrier status can have an effect on future offspring and therefore
consider reproductive age, as opposed to legal adulthood, as an appropriate age for young
persons to give informed consent regarding carrier testing.
With regard to hemophilia A and B, which are X-linked conditions, parents may be
more inclined to favor genetic testing at a younger age with one study reporting a majority
(84%) of parents wanting their daughters to be tested before age 14 [66]. In this study, the
primary reason parents who supported genetic testing at a younger age gave was to enable their
daughters to prepare for their own future children. Given the de novo rate of hemophilia, many
mothers are not aware they are carriers until they have a son who is diagnosed with hemophilia.
It is important to note, however, that girls who are carriers of X-linked conditions can exhibit
some symptoms due to skewed X-inactivation. Therefore, genetic testing for minors at risk of
being a carrier for hemophilia is not always presymptomatic. This is similar to patients with
MEN1 who may not show any medically harmful symptoms of disease until they are older than
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18 years, but it is not uncommon for patients to begin to show signs such as PHPT at an earlier
age.
To our knowledge, no studies have investigated parental preferences regarding MEN1
genetic testing in minors. Two studies examining the quality of life for patients with MEN1
highlighted the challenges of the condition including physical and psychological pain, guilt and
an overall pessimistic outlook [67] [68]. However, it has also been reported that patients with
MEN1 develop adequate coping mechanisms and tend to adjust well to their situation.
Currently, decisions about MEN1 genetic testing in minors is based on individual physician’s
discretion. Assessing the opinions of patients with MEN1 will provide important insight from
those who have first-hand experience of the condition.
The aim of this study is to evaluate attitudes about MEN1 genetic testing for healthy
minors among adults with an MEN1 diagnosis and/or their partners. We hypothesize that
affected participants will be more likely to favor genetic testing in minors than their partners or
spouses and that those with a younger age of diagnosis will be more likely to favor genetic
testing in minors than patients with an older age of diagnosis. Findings from this study may
help physicians and genetic counselors to better counsel their patients about an appropriate age
for testing.
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Materials and methods
This cross-sectional study was designed to evaluate attitudes towards predictive MEN1
genetic testing in healthy minors among individuals at risk of having a child with MEN1. This
study was approved by the MD Anderson Cancer Center’s (MDACC) Institutional Review
Board (2006-0783) and the Committee for the Protection of the Human Subjects at the
University of Texas Health Science Center (HSC-MS-11-0433).
Study Population
Study participants were recruited from two sources. One hundred nine eligible patients
with MEN1 were identified from a database maintained by the Department of Surgical
Endocrinology at MDACC. Eligible patients were able to read and write in English, were age
18 years or older, and had an identified mutation in the MEN1 gene. Additionally, MEN1
patients were asked to invite their spouses or long-term partners to participate in the study.
Eligible spouses and long-term partners also were above the age of 18 and were able read or
write in English.
Participants also were recruited from an online advertisement through the online
Association for Multiple Endocrine Neoplasia Disorders (A.M.E.N.D.) support group. These
participants were directed to an online version of the questionnaire. Eligibility was confirmed
through a series of screening questions prior to beginning the questionnaire. Persons with an
MEN1 genetic mutation and their spouses or partners were invited to participate. Individuals
who stated they did not have a confirmed MEN1 mutation were excluded from the study.
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Data Collection
Eligible patients from the MDACC database received a study packet by mail. Each
packet contained a cover letter (Appendix A), a questionnaire for the affected participant
printed on white paper (Appendix B), a questionnaire for the affected participant’s spouse or
long-term partner printed on yellow paper (Appendix C), and two postage-paid business reply
envelopes. The cover letter included a description of the study, a link to the online version of
the questionnaire, and directions for both the MEN1-affected participant and partner to
complete and return the questionnaire. Packets were mailed only to affected individuals, who
were given the option of distributing it to the partner or co-parent they felt most appropriate to
complete the questionnaire.

Each questionnaire was de-identified, but was coded with an

identification number for tracking purposes and to match questionnaires from affected
participants with their spouse/partner. MDACC patients who completed the online version of
the questionnaire were asked to provide their tracking number. Both the online questionnaire
and the paper questionnaire contained the standard questionnaire consent paragraph approved
by the MDACC IRB.
Study packets were mailed in mid-December, 2011. A second packet with a reminder
letter (Appendix D), two business reply envelopes, and a second copy of each questionnaire
was mailed to participants six weeks after the initial mailing. In addition, an advertisement
containing a link to an online version of the questionnaire was posted on the A.M.E.N.D.
website under its research section in mid-December, 2011. Data collection was completed on
February 23, 2012.
The online version of the questionnaire was developed using SurveyMonkey®, a
confidential, online survey-making tool. Those who completed the online questionnaire were
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required to provide informed consent and confirm eligibility through a series of preliminary
questions. Once eligibility was confirmed, participants were directed to the online
questionnaire, which was identical to the paper version.
Measures
The study questionnaire was comprised of six sections, which included several
validated measures as well as tools adapted from previous studies. The six sections included 1)
demographic characteristics of the MEN1-affected participant or partner and the MEN1-related
medical history (MEN1 patients only); 2) demographic and MEN1-related medical history of
the participant’s children; 3) knowledge of MEN1-associated risks and inheritance; 4) the
Impact of Event Scale to assess distress response related to an MEN1 diagnosis; 5) the
Pediatric Testing Attitudes Scale (P-TAS) to measure attitudes towards predictive testing in
minors; 6) a decisional balance measure weighing the pros and cons of genetic testing in
minors. The questionnaire also included an open-ended, free hand response question asking
participants to identify their perceived ideal age for genetic testing and reasons for selecting the
age.
Demographic information
For each participant, we assessed age, gender, country of residence, marital status,
highest level of education completed, occupational status, and household income. Partners
were asked to identify their relationship to the affected individual and any at-risk children.
Affected participants self-reported the type of tumor with which they had been diagnosed
(parathyroid, pituitary or pancreatic/stomach/intestinal) and at what age. They were also asked
if any tumor had metastasized and what age they were when they were first diagnosed with
MEN1.
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Family History Information
All participants were asked to identify the number of people in their family that were
affected with MEN1, how many people in their family had died from complications related to
MEN1, how many people in their family had been diagnosed with an MEN1-related tumor
before age 18, and their perceived severity of MEN1 in the family. Perceived severity was
measured on a Likert scale ranging from 1 (not at all) to 5 (greatly).
Demographic and medical history also was collected for at-risk children. For
participants recruited from MDACC, only affected participants were asked to complete the
section about their children and their responses were linked to their corresponding partner’s ID
number. Data collected included age, gender, diagnosis of a MEN1-related tumor and at what
age, age and results of child’s genetic testing, and communication of the family’s MEN1 status
with the child. Participants were asked to complete these questions for each of their children.
Knowledge
To assess the participants’ understanding of the natural history and inheritance of
MEN1, participants were asked to answer true, false or unsure to eight statements about MEN1.
Scores were summarized as the number correct out of the total. After data collection was
completed, it was determined that the following item was ambiguous, and therefore was not
included in the data analysis: “A person who carries an altered MEN1 susceptibility gene will
definitely develop features of MEN1 in his or her lifetime.”
Impact of Event Scale
The Impact of Event Scale was designed by Horowitz, et al. [69] as a measure of
distress responses anchored to a specific event. This scale includes 15 items that assess both
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avoidance and intrusion responses to a specific event. Intrusion was characterized by the
presence of unintentional thoughts, dreams, and images, as well as waves of emotion.
Avoidance includes denial of the impact of an event, feelings of numbness, and behavioral
inhibition. It has been commonly used to assess levels of post-traumatic stress in various
groups of patients. The Impact of Event scale was used in this study based on clinical
observations of high levels of anxiety in patients with MEN1 and studies that have found
patients with MEN1 to have an overall pessimistic outlook [67] [68]. Participants in this study
were asked to think about their experience with MEN1 in the family and indicate how often
each item had happened to them in the past seven days. Responses were measured on a 4-point
scale ranging from not at all to often. Higher scores indicated higher levels of distress related
to an MEN1 diagnosis.
Decisional Balance
The decisional balance scale is a component of the transtheoretical model (TTM),
which is a conceptual framework often used in health promotion and behavioral change
studies to assess a participant’s willingness to adopt a new health behavior. One
component of the TTM is the stage of change construct which identifies a participant’s
degree, or stage of readiness to adopt a target behavior and generally includes the
following: precontemplation, contemplation, preparation, action, maintenance and
termination[70] [71]. Decisional balance is a second component of the TTM framework
and is aimed at understanding the importance of pros and cons of a given behavioral
change to the participant [72]. The decisional balance may vary depending on an
individual’s stage of readiness to change: at contemplation, the pros of undertaking a
specific behavior change may be weighed equally with the cons of doing so; whereas, in
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later stages, when a participant is more likely to change their behavior, the pros are more
likely to outweigh the cons [73].
The decisional balance measure used in this study included items describing pros and
cons that addressed considerations related to genetic testing in healthy minors and was adapted
from measures used in previous studies about genetic testing [74] [75]. Fourteen items were
included (seven perceived pros and seven perceived cons). Participants were asked to rate the
level of importance for each factor on a 5-point Likert scale (1=not important, 5=very
important) when considering having their child tested for MEN1. Higher scores on the
decisional balance suggest that the pros outweigh the cons in decision making, whereas lower
scores indicate a stronger view of the negative consequences of genetic testing.
Pediatric Testing Attitudes Scale (P-TAS)
The Pediatric Testing Attitudes Scale (P-TAS) was used to measure participants’
attitudes about predictive MEN1 testing in minors. The scale was originally created by Peshkin
et al. [76] to measure parents’ opinions about genetic testing in minors for hereditary breast and
ovarian cancer (BRCA1/2). For our purposes, the questions were adapted to apply to MEN1.
The P-TAS scale is an 11-item measure that comprises two factors: Attitudes and Beliefs (odd
numbered items) and Decision Making and Communication (even numbered items). Items
measuring attitudes and beliefs are intended to capture parents’ theoretical opinions about
genetic testing while the decision making and communication items describe the importance of
involving the child and others in the decision to have genetic testing and disclosure of the
results. Participants were asked to rate their responses from 1 to 5 (1 = strongly disagree and 5
= strongly agree) for each item. Higher scores on the P-TAS measure indicated stronger
preferences towards predictive testing in minors.
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Ideal Age for Testing
A single item, open-ended question asked respondents what their opinion regarding the
ideal age for predictive MEN1 genetic testing was and why they chose this age (Appendix E).
This item was also used to capture any additional comments about an appropriate age for
genetic testing.
Data Analysis
Summary statistics (i.e. mean, percent, range, SD) were computed for all demographic,
medical, and family history variables. Knowledge scores were calculated as the percent
correctly answered. Each response from the IES scale was summarized with point values 0, 1,
3, and 5 and scores were calculated separately for the Intrusion and Avoidance subscales and
for the overall measure. Possible scores could range from 0 to 35 for the Intrusion subscale,
from 0 to 40 for the Avoidance subscale, and 0 to 75 for overall IES score. The decisional
balance measure in this study was adapted from a previously developed measure [75]. The
decisional balance score was first calculated by subtracting the sum of cons items from the sum
of pros items. Raw scores were converted into T scores with a mean of 50 and a standard
deviation of 10 for further analysis. Overall decisional balance scores were calculated by
subtracting T scores of the cons from T scores of the pros. Participants were given the option
of skipping questions they were uncomfortable with and so response rates varied by question.
Missing data in the knowledge section was coded as false. Missing questions in the IES,
Decisional Balance and P-TAS were replaced with the average score from the other questions
answered in the same subscale.
Scores for each factor of the P-TAS measure were calculated independently and jointly
as a total P-TAS score. For Factor 1 (Attitudes and Beliefs) and Factor 2 (Decision Making
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and Communication), the possible range of scores was 6 to 30 and 5 to 25, respectively. The
possible range for total PTAS score was 11 to 55.
For the ideal age, because many participants gave a range of ages (i.e. 8-10) or vague
description (i.e. before puberty, when the child is old enough to understand, at a young age,
etc.) this item could not be analyzed as a continuous variable. For purposes of analysis, ideal
age was coded as either childhood (≤14 years), high school and above (>14 years), or
indeterminate by two independent reviewers. Responses such as “as soon as possible” and
“before puberty” were included in the ≤14 category. Age 14 was chosen as the cutoff given
that this is the age when most children have already started undergoing puberty, are entering
high school and have entered the transition period between childhood and adulthood, and are
taking on additional adult roles and decision making.
The main outcomes of interest included 1) overall attitude toward MEN1 genetic testing
(P-TAS score) and 2) ideal age to perform genetic testing. Predictor variables included spouse
vs. affected patient, demographics, medical history (affected participants only), family history
characteristics, knowledge of MEN1 genetics, and IES and decisional balance scores. Most
demographic data were dichotomized into categorical variables (i.e. residence in the United
States vs. other, college graduate and above vs. other, income ≤$75,000 vs. >$75,000, etc).
Age, knowledge, IES scores and decisional balance were analyzed as continuous variables.
Age was also examined as a dichotomous variable (age younger than 50 years vs. older than 50
years). All analyses were performed using Statistical Analysis System (SAS) software (version
9.2; SAS Institute Inc, Cary, NC). Pearson’s correlation coefficients were calculated to
compare responses from affected participants to those of spouses. Data analysis was performed
separately for affected participants and partners, as well as for both combined. For ease of data
presentation, we report the results from the combined analysis and comment where there were
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differences when the data was analyzed separately. For the combined data set, the effect of the
predictive variables on the two outcomes of interest was examined using generalized linear
mixed model analyses in order to account for non-independence between patient and spouse.
When patients and spouses were analyzed separately, a general linear model was used to
analyze the relationship between predictor variables and P-TAS scores. A general logistic
regression analysis was used to evaluate the relationship between the predictor variables and
ideal testing age. P-values less than or equal to 0.05 were considered significant. A
multivariate model with backward elimination technique using GLIMMIX in SAS was used to
obtain adjusted odds ratios for ideal testing age and adjusted beta coefficients for overall PTAS scores. Variables that were associated with Ideal Age and P-TAS scores in the univariate
analysis (p≤0.25) were used as covariates in the multivariate analysis. Characteristics of the
children were not used in the multivariate analysis due to significant multicollinearity with
other predictive variables. Multivariate regression models were used to analyze outcomes in
parents and spouses separately.
Additionally, the free response for ideal age were independently coded by two
reviewers with training in genetic counseling and analyzed to identify common reasons in favor
or against MEN1 genetic testing in healthy minors. In many cases, participants had responses
that could be assigned to more than one category.
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Results
Of the 109 study questionnaires mailed, 10 questionnaires were returned due to
inaccurate addresses leaving a denominator of 99 affected participants. It is unclear how many
people viewed the online advertisement. A total of 80 participants completed this questionnaire
through the two recruitment strategies; forty-nine (31 affected participants and 18 partners)
from MDACC and thirty-one (27 affected participants and 4 partners) from the online
advertisement. Fifty-eight respondents (73%) had a known mutation in the MEN1 gene whereas
22 respondents were partners or co-parents of someone with an MEN1 genetic mutation.
Among the spouses or partners, one (5%) stated they were previously married to someone with
an MEN1 genetic mutation and one (5%) had either step-children or adopted children at risk of
developing MEN1. All other partners were either currently married to someone with MEN1 or
had biological children at risk of developing MEN1.
Demographics
The demographic characteristics of the study population are summarized in Table 1.
The average age of all respondents was 47.11 years (SD=14.13) with a range of 19 to 76 years.
The majority of respondents were female (60%) and married (77%). Fifty-seven percent had
an education level of college degree or greater with 16% achieving an upper level degree.
Almost half of participants (49%) were employed full time and 44% had a combined annual
salary greater than $75,000. Patients recruited online were from several countries around the
world. Although all patients recruited from the MDACC database were from the United States,
A.M.E.N.D is an international support group based out of the United Kingdom and had
members from many countries. Fifty-five (69%) participants were from the United States and
18 (23%) were from the United Kingdom. Two (3%) respondents were from Canada and there
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was one (1%) participant from each of the following countries: Germany, Israel, Netherlands,
New Zealand.
Table 1. Participants Demographic Characteristics
Demographics
Affected Participants
Spouses/Partners
Age: Mean (range)
Gender
Males
Females
Residence*
USA
Other
Marital Status*
Single
Married
Separated
Divorced
Income**

n
%
58
73%
22
28%
47.11 (19-76)
n
32
48

%
40%
60%

55
24

70%
30%

10
61
2
6

13%
77%
3%
8%

Highest Level of education*
Some High School
High School Graduate
Some College
College Graduate
Associate’s Degree
Upper Level Degree
Occupation*
Employed (Full Time)
Employed (Part Time)
Unemployed (Not seeking)
Unemployed (Seeking a
job)
Homemaker
Student
Retired

<$25,000
12
16%
$25,000-$50,000
8
11%
$50,000-$75,000 18
25%
>$75,000
35
48%
* 1 respondent did not answer this question
** 7 respondents did not answer this question

n
4
5
25
25
7
13

%
5%
6%
32%
32%
9%
16%

39
8
4
1

49%
10%
5%
1%

11
4
12

14%
5%
15%

Medical History of Participants with MEN1
The self-reported medical history of the affected participants is summarized in Table 2.
Only one participant reported no history of an MEN1-related tumor. Most (77%) had more
than one affected gland. The average age of diagnosis for each tumor, as well as age of MEN1
diagnosis, was in the late 20s-30s. The minority (14%) was diagnosed with MEN1 before age
18 years.
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Table 2. Medical History Characteristics for Participants Affected with MEN1 (n = 58)
Tumor Site
Parathyroid
Pituitary
Pancreatic/Gastrointestinal

N
52
22
42

%
90%
38%
72%

Metastasized tumor

13

31%

Number of affected sites
0
1
2
3

1
12
31
14

2%
21%
53%
24%

Avg. Age of MEN1 Diagnosis (range)
Diagnosed <18 years

11

Avg. age, years (Range)
32.39 (11-66)
29.82 (15-57)
37.00 (10-66)

33.66 (10-71)
14%

Family History
The MEN1 family history data reported by affected participants and spouses are
summarized in Table 3. Most people reported having at least one affected relative (90%) and
over half (55%) had a relative who had passed away from MEN1-related causes. Roughly a
quarter (24%) indicated they had a relative who was diagnosed with MEN1 before the age of
18 years. Most (79%) reported that MEN1 had greatly or somewhat greatly affected their
family’s health and well-being.
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Table 3. Participants’ Family History of MEN1*
n
Number of Affected Relatives

%

None

8

10%

1-2
3-4

28
25

35%
32%

5 or more

18

23%

Experienced an MEN1-related
Death in a Family Member
Avg. Age of family
member’s death (range)
Had a Relative with an MEN1
Diagnosis under 18 years
Avg. age of family member’s
diagnosis (range)
Closest Degree of Relation
First Degree
Second Degree
Third Degree
Unknown

Perceived Severity of MEN1 on Family’s
Health and Well-Being
1
2
3%
2
6
8%
3
16
20%
4
18
23% Have Children
5
38
48%
*Includes family history reported by spouses and affected participants
**1 respondent did not answer this question
***2 respondents did not respond to this question

n
44

%
55%

51.79
(25-80)
19

24%
14.32
(10-17)

9
1
2
4

47%
5%
11%
21%

59

74%

Fifty-nine respondents (74%) had at least one child at risk of inheriting MEN1 and
reported a total of 92 children. Characteristics of participants with children are described in
Table 4 and characteristics of the children are described in Table 5. Sixty-six percent of the
participants who had children had at least one child who had had genetic testing for MEN1,
although only 29% had a child affected with MEN1 and only 4 (7%) had a child diagnosed
before age 18. The reported children ranged in age from 0-56 (M= 20.57 years; SD=14.82)
and only 24% had been diagnosed with MEN1. Of the 66% of the children who had MEN1
genetic testing, roughly half (52%) were found to be positive. Age at testing was slightly
younger than age of diagnosis of an MEN1-related tumor (M=14.82 vs. M=19.89 years).
Participants were also asked whether or not their children had been told about the MEN1
diagnosis in the family and 75% responded that they had.
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Table 4. Characteristics of Participants with Children*
n
%
Child <18 years
28
48%
Child Diagnosed with MEN1
17
29%
Child Diagnosed with MEN1 < 18 years
4
7%
Child had genetic testing for MEN1
38
66%
Child had genetic testing for MEN1 <18 years
21
36%
Child had a positive genetic test for MEN1
24
41%
Child told about MEN1 diagnosis <18 years
21
36%
*Table represents participants who had at least one child in each category.

Table 5. Characteristics of 92 Children Reported by Participants Affected with
MEN1
Average Age: 20.567 (0-56)
Gender
Male
Diagnosis of MEN1-related tumor
Yes
Avg. Age of diagnosis: 19.889 (3-40)
Genetic Testing for MEN1
Yes
Positive
Avg. Age of Testing: 14.820 (0-43)
Child Told about Family History of MEN1
Yes
Avg. Age of disclosure 17.587 (3-42)

n
50

%
54%

22

24%

61
32

66%
52%

59

75%

Knowledge
The mean knowledge score was 82.86% (SD=18.38; Table 6). Thirty-three participants
(41%) answered all seven questions correctly and 64% scored higher than 75% correct.
The knowledge scale initially was designed to include 8 questions, with one that read,
“A person who carries an altered MEN1 susceptibility gene will definitely develop features of
MEN1 in his or her lifetime.” Only 30% of participants selected true for this item and of those
who responded false, several wrote that it was very likely. Due to the ambiguous phrasing of
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the question, this item was dropped from the final analysis as it did not accurately assess the
participants’ understanding of MEN1 inheritance or natural history.
Table 6. Responses to Knowledge Questions
True
n
%

False
n
%

An altered MEN1 susceptibility gene
69
86%
9
can be inherited from either parent.
If Lisa looks more like her mother
than her father, she has probably
13
16%
57
received more of her genetic
information from her mother.
Susan is the first born in her family.
Her mother, who has MEN1, was also
the first born. Thus, Susan has a
5
6%
66
higher risk of developing MEN1 than
her younger brothers and sisters.
Rick has had genetic testing for an
MEN1 gene alteration that was found
in his family. His results were
65
81%
8
negative; therefore, he is not at
increased risk to develop features of
MEN1.
Kelly has had genetic testing for an
MEN1 gene alteration that was found
in her family. Her results were
54
68%
22
negative; therefore, her children are
not at risk to inherit MEN1 from her.
John’s father has an altered MEN1
gene. The chance that John has
75
95%
0
inherited this gene alteration is 50%
or 1 in 2.
Once a gene alteration has been
detected in a person with MEN1,
their family members can be tested
78
98%
1
for the gene alteration to know for
certain whether or not they also have
MEN1.
Total Score Avg.: 82.86 (SD=18.382, range=28.571 – 100)

Unsure
n
%

11%

2

3%

71%

10

13%

83%

9

11%

10%

7

9%

28%

3

4%

0%

4

5%

1%

1

1%
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Impact of Event Scale
Respondents’ mean scores on the Intrusion subscale was 11.21 (SD=8.84, range 0-35).
Mean score on the Avoidance subscale was 10.93 (SD=8.31, range=0-32). The overall mean
IES score was 22.14 (SD=15.58) and ranged from 0 to 58 (maximum possible was 75). In
1999, Corneil, et al. [77] categorized IES scores into clinically meaningful ranges of distress.
In our study, 22 out of 80 participants fell within the subclinical distress range (scores 0-8), 22
were classified as in the mild range (9-25), 29 were in the moderate range (26-43) and 7 were
classified as falling within the severe range (44+). Response rates per question are presented in
Table 7. Between affected participants and their partners, Intrusion subscale (r=0.022,
p=0.935) and total IES (r=0.234, p=0.383) scores were not significantly correlated, but there
was a significant positive correlation between these groups for the Avoidance subscale mean
scores (r=0.544, p=0.029).
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Table 7. Responses to Impact of Event Scale
Not at all
n
%

Rarely
n
%

I thought about it when I didn’t
14 18% 15
19%
mean to.
I avoided letting myself get
upset when I thought about it
12 15% 13
17%
or was reminded of it.
I tried to remove it from my
36 46% 16
20%
memory.
I had trouble falling asleep or
staying asleep because of
36 45% 23
29%
pictures or thoughts about it
that came into my mind.
I had waves of strong feelings
20 25% 22
28%
about it.
I had dreams about it.
51 64% 21
26%
I stayed away from reminders
47 59% 22
28%
of it.
I felt as if it hadn’t happened to
49 62% 20
25%
me or it wasn’t real.
I tried not to talk about it.
44 55% 10
13%
Pictures about it popped into
34 43% 16
20%
my mind.
Other things kept making me
30 38% 19
24%
think about it.
I was aware that I still had a lot
of feelings about it, but I didn’t 36 45% 19
24%
deal with them.
I tried not to think about it.
33 42% 13
16%
Any reminder brought back
31 39% 14
18%
feelings about it.
My feelings about it were kind
39 49% 13
16%
of numb.
Avg. Total IES: 22.14 (SD=15.58, range=0-58)
Avg. Intrusion score: 11.21 (SD=8.84, range=0-35)
Avg. Avoidance score: 10.93 (SD=8.31, range=0-32)

Sometimes
n
%

Often
n
%

33

41%

18

23%

35

45%

18

23%

18

23%

9

11%

15

19%

6

8%

27

34%

10

13%

6

8%

2

3%

8

10%

2

3%

8

10%

2

3%

21

26%

5

6%

21

27%

8

10%

20

25%

11

14%

21

26%

4

5%

26

33%

7

9%

25

31%

10

13%

21

27%

6

8%
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Decisional Balance
On the decisional balance measure, the mean pros score was 30.17 (SD=4.80) and that
of cons was 17.55 (SD=5.56). The mean difference between pros and cons (decisional
balance) was 12.21 (SD=6.67), and did not differ for affected participants and spouses when
analyzed separately: (M=12.16, SD=6.77; M=12.34, SD=6.59, respectively). Although two
affected participants had a score of 0, no participants had a negative decisional balance score.
Table 8. Responses by Question of Decisional Balance

Not
Important

Slightly
Important

Somewhat
Important

Importan
t

Very
Important

n

%

n

%

n

%

n

%

n

%

0

0%

3

4%

2

3%

18

23%

55

71%

2

3%

3

4%

5

6%

23

29%

45

58%

I’m afraid I would
get too upset

34

42%

17

22%

15

19%

8

10%

5

6%

I / My child could
plan for the future

4

5%

5

6%

6

8%

30

39%

32

42%

I’m afraid my child
would get too upset

9

12%

7

9%

30

39%

19

25%

11

14%

I am concerned that
having the test
might cause
problems with my
child’s insurance

14

18%

4

5%

14

18%

13

16%

31

28%

I am concerned
about my family’s

37

49%

15

20%

13

17%

7

9%

4

5%

I would be
relieved to know
my child did not
have MEN1
My own
experience with
MEN1 makes me
more concerned
about my child’s
risk for the
disease
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reactions
I want to learn
whether my child is
at risk for MEN1

0

0%

5

7%

4

5%

17

22%

50

66%

I am worried about
how it would affect
my relationship
with my child

35

47%

14

19%

12

16%

7

9%

6

8%

I’m not sure if the
genetic test is
accurate

32

45%

7

9%

12

17%

11

15%

9

%

Something could be
done to improve my
child’s health

0

0%

2

3%

5

7%

17

23%

51

68%

I have a
responsibility to let
my child know if
he/she has MEN1

2

3%

6

8%

7

9%

19

26%

40

54%

I just want to know

7

9%

6

8%

14

18%

12

16%

37

49%

The cost of genetic
testing is too
expensive for my
family to afford

33

45%

7

9%

16

22%

8

11%

10

14%

Avg. Sum of Pros: 30.17 (SD=4.80, range=15-35)
Avg. Sum of Cons: 17.95 (SD=5.56, range=7-34)
Avg. Decisional Balance: 12.21 (SD=6.67, range=0-28)
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Pediatric Testing Attitudes Scale (P-TAS) and Correlates
The mean score for Factor 1 (Attitudes and Beliefs) on the P-TAS was 25.4 out of a
maximum of 30 (range 7.2-30; SD= 4.97). The mean score for Factor 2 (Decision Making and
Communication) was 19.0 out of a maximum of 25 (range 11-25; SD= 3.09) The mean total PTAS score was 44.40 out of a maximum of 55 (range 19.2-55; SD=7.22). Responses between
affected participants and partners were not correlated (Factor1: r=0.35, p=.20; Factor 2: r=0.25,
p=.362; Total: r=0.33, p=.225).
Table 9. Responses to P-TAS questionnaire

Children under age 18
should be given the
opportunity to be
genetically tested for
the MEN1gene
alteration
Parents should decide if
their children are
allowed to have an
MEN1 genetic test or
not, even if a doctor
disagrees
Even though some of
the conditions
associated with MEN1
may not affect people
until they reach
adulthood, children
should still be offered
MEN1 genetic testing
Children should be
involved in making the
decision about whether
or not they have MEN1
genetic testing
I am in favor of MEN1

Neither
Agree nor
Disagree
N
%

Strongly
Disagree

Disagree

n

%

n

%

2

3%

2

3%

6

3

4%

6

8%

2

3%

1

4

5%

2

3%

Agree

Strongly
Agree

N

%

n

%

8%

28

35%

41

52%

11

14%

27

35%

30

39%

1%

4

5%

30

38%

42

53%

10

13%

16

20%

32

41%

16

21%

2

3%

8

10%

26

33%

40

51%
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genetic testing for
children
If children are tested
and they turn out to
carry an MEN1 gene
alteration (that is, they
test positive), they
should be told about
their test result
immediately

4

5%

23

29%

17

22%

21

27%

Even if there is no
known prevention for
the conditions
associated with MEN1,
1
1%
3
4%
7
9% 29 37%
children should be
offered MEN1 genetic
testing
If children are tested
and they turn out to
carry a MEN1 gene
alteration (that is, they
0
0%
2
3%
8 10% 32 41%
test positive), then this
information should be
shared with the child’s
pediatrician
I want my child to have
genetic testing for
1
1%
2
3% 20 27% 18 24%
MEN1 before age 18
If children are tested
and they turn out not to
carry an MEN1 gene
alteration (that is, they
2
3% 10 13% 13 16% 26 33%
test negative), they
should be told about
their test result
immediately
The benefits of children
participating in MEN1
1
1%
4
5% 15 19% 19 25%
genetic testing
outweigh the risks
Total Summed Avg.: 44.40 (SD=7.22, range=19.2-55)
Attitudes and Beliefs: 25.43 (SD=4.97, range=7.2-30)
Decision Making and Communication: 18.97 (SD=3.09, range= 11-25)

14

18%

39

49%

37

46%

33

45%

28

35%

38

49%
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Results from the univariate generalized linear mixed model regression analysis of the
association between independent variables and subscale and overall P-TAS scores are
summarized in Table 10. Younger current age predicted higher P-TAS scores (β = -0.147, p =
0.03) and appeared to be primarily driven by the respondents’ Factor 1 scores, rather than
Factor 2 scores. Knowledge scores were positively associated with P-TAS scores, (β = 1.789.
p=0.012), although this association did not reach levels of statistical significance for spouses
alone (p=0.228). For family history, P-TAS scores were higher among participants who had
more than two relatives affected with MEN1 (β = 3.444, p=0.050). However, the number of
relatives diagnosed before age 18, the number of relatives who have had an MEN1-related
death, the overall perceived disease severity, and characteristics of participants’ children were
not associated with overall P-TAS scores. Having at least one child who had genetic testing,
regardless of the result or age of testing, was associated with higher Factor 2 (Decision-Making
and Communication) scores (β = 0.871, p = 0.032).
Decisional balance scores also were positively associated with both P-TAS factor
scores, as well as overall P-TAS score (β = 0.36, p<0.0001). There also was a positive
association between the mean pros and P-TAS scores for both factors and total P-TAS
(p=<0.0001) suggesting that scores of the pros are the driving factor in the decisional balance
with regard to opinions about genetic testing.
P-TAS scores between affected participants and spouses were not significantly
different. Personal medical history was also not associated with higher P-TAS scores, nor was
the number of affected sites. Age of diagnosis trended towards a negative association with
Factor 1 scores (p=0.061), but was not associated with overall P-TAS scores.
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Multivariate analysis for P-TAS scores included the covariates current age, marital
status, highest level of education completed, number of affected relatives, and decisional
balance (Table 11). This model showed that a positive association between decisional balance
and overall P-TAS scores remained statistically significant (p= 0.0002) while number of
affected relatives was not (p= 0.07). Additionally, current age was no longer found to be
significant.
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Table 10. Generalized Linear Mixed Model for Predictors of P-TAS Scores for All
Respondents
n
Demographic
and Medical
History
Affected
participants
Partners
Age

57

Decision Making
and Communication
(Factor 2)
Beta
p-value
(SE)

Total PTAS
Beta
(SE)

p-value

0.406
(1.157)

0.731

0.947
(0.731)

0.216

1.444
(1.658)

0.399

-0.126
(0.039)
1.043
(0.432)
0.264
(0.036)
-0.029
(0.036)
0.014
(0.064)
-0.123
(0.064)
2.134
(1.110)

0.006

-0.019
(0.026)
0.741
(0.265)
0.091
(0.027)
0.017
(0.023)
0.052
(0.039)
0.002
(0.043)
1.170
(0.700)

0.460

-0.147
(0.058)
1.789
(0.619)
0.357
(0.055)
-0.066
(0.093)
0.066
(0.093)
-0.121
(0.100)
3.444
(1.605)

0.0248

-0.007
(0.027)
0.309
(0.813)

0.798

22

Knowledge
Decisional
Balance
Impact of Event
Intrusion
Avoidance
Number of
affected relatives
≤2
>2
Age of
Diagnosis*
Children

Attitudes and
Beliefs
(Factor 1)
Beta
p-value
(SE)

0.030
<0.001
0.432
0.825
0.092
0.075

0.014
0.005
0.454
0.208
0.967
0.117

0.012
<0.001
0.488
0.488
0.244
0.050

35
48
-0.077
(0.040)
1.462
(1.306)

0.061
0.282

0.710

Yes
59
No
20
Child with
1.555
0.218
2.089
0.032
Genetic Testing
(1.202)
(0.871)
Yes
38
No
20
Child tested
2.888
0.069
-0.297
0.800
before 18 years
(1.345)
(1.127)
Yes
21
No
13
* Calculated for affected participants only using a general linear model.

-0.084
(0.061)
1.782
(1.903)

0.175

3.567
(1.814)

0.071

2.854
(2.219)

0.240

0.365
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Table 11. Multivariate Analysis of Predictors for Total P-TAS Scores

Current Age
Married/Long-term Partner
College Graduate or higher
Greater than 2 affected
relatives
Decisional Balance

Adjusted-Beta (SE)
-0.076 (0.054)
2.408 (1.707)
-2.461 (1.375)
2.700 (1.344)

p-value
0.188
0.186
0.101
0.070

0.320 (0.057)

0.0002

Ideal Age for Genetic Testing
Overall, 44 participants felt the ideal age for genetic testing for MEN1 should be
younger than 14 years and 18 participants felt the ideal age for testing was older than 14 years.
Eighteen participants did not respond or provided answers that could not be coded as younger
than or older than 14 and were not included in the analyses.
Older participants were more likely to favor testing over the age of 14 (p=0.026). When
current age was dichotomized between younger than and older than 50 years, the odds of a
participant over 50 years favoring genetic testing after age 14 was 5.33 times higher compared
to those under the age of 50 (p=0.025).
Participants who had a lower mean decisional balance score were more likely to support
testing at ages older than 14 (p=0.0267). Similar responses were seen in partners alone
(p=0.039) and responses for affected participants followed a similar yet not significant trend
(p=0.060). Overall, participants whose mean pros scores were lower were more likely to select
an age greater than 14 for genetic testing (p=0.027).
Among affected participants only, those with higher mean knowledge scores favored
genetic testing before age 14 compared with patients with lower mean knowledge scores
(p=0.034). A similar positive trend was also found for the combined dataset (p=0.0523)
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The majority of affected participants (73%) favored genetic testing in children under the
age of 14 years. Similarly, 65% of partners favored genetic testing before age 14 years.
However, no statistically significant difference was noted between affected participants and
partners with regard to their preference in age for predictive genetic testing. Demographic
characteristics including gender, country of residence, marital status, education, employment
and income also were not associated with preferred age of testing, nor were personal medical
history, including number of affected glands or age of diagnosis, and family history
characteristics.
In a multivariate analysis, none of the covariates including current age, highest level of
education completed, knowledge, intrusion scores and decisional balance were associated with
preferred age for testing, possibly due to the limited sample size. In a separate multivariate
logistic regression model including affected participants only, adjusted OR suggest that having
an education level of college graduate or higher and being employed were associated with
favoring genetic testing after age 14 (p=0.043 and p=0.048 respectively), whereas higher
knowledge scores were associated with favoring genetic testing in children younger than 14
years (p=0.008).
Children’s wellbeing, genetic testing, and knowledge of MEN1 in the family also were
analyzed as predictor variables for respondents with children. None of these predictors reached
levels of statistical significance. However, the variable most closely approaching levels of
statistical significance was whether or not a child had been diagnosed with MEN1, regardless
of age (p=0.061). Respondents who do not have a child diagnosed with MEN1 were more in
favor of testing children before age 14 years. When affected participants were analyzed
separately, they were 6.25 times more likely to support genetic testing in children over the age
of 14 if they had a child that was diagnosed with MEN1 (p=0.034).
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Table 12. Generalized Linear Mixed Model for Continuous Predictors of Ideal Age for All
Participants
Demographics and Medical
History

% Ideal
Age ≤14
years
33

% Ideal
Age >14
years
12

Partners
Current Age
<50 years

11

6

31

5

≥50 years
Child Diagnosed with MEN1

11

6

Affected Participants

Yes
No

6
27

OR (95% CI)

pvalue

0.647
(0.144-2.901)

0.528

6.484
(1.338-31.429)

0.025

5.956
(0.900-39.422)

0.061

8
6

Table 13. Generalized Linear Mixed Model for Dichotomous Predictors of Ideal Age for
All Participants
Demographic and
Medical History
Age

OR (95% CI)

P

1.070
0.026
(1.010-1.133)
Knowledge
0.572
0.053
(0.325-1.007)
Decisional Balance
0.572
0.027
(0.854-0.988)
Sum of Pros
0.0899
0.027
(0.821-0.985)
Sum of Cons
1.028
0.415
(0.955-1.108)
Impact of Event
0.977
0.322
(0.930-1.027)
Intrusion
0.925
0.097
(0.841-1.017)
Avoidance
1.003
0.936
(0.915-1.100)
Age of Diagnosis*
1.037
0.109
(0.992-1.083)
* Calculated for affected participants only using logistic regression analysis.
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Table 14. Multivariate analysis for Predictors of Ideal Age (combined data)

Age
College graduate and above
Knowledge
Intrusion
Decisional Balance

Adjusted OR
(95% CI interval)
1.065
(0.981-1.155)
5.441
(0.395-74.88)
0.534
(0.202-1.412)
0.906
(0.766-1.073)
0.936
(0.847-1.035)

P
0.105
0.157
0.158
0.195
0.1522

Table 15. Multivariate Analysis for Predictors of Ideal Age (affected participant
only)

College graduate and above
Employed (full time/part
time)
Knowledge
Age of Diagnosis

Adjusted OR
(95% CI interval)
15.56
(1.087-222.746)
49.974
(1.03->999.99)
0.141
(0.033-0.595)
1.09
(0.996-1.192)

P
0.043
0.048
0.008
0.060

Reasons for Testing
Multiple reasons were identified for selecting specific ages and participants frequently
gave more than once answer. Nine themes were identified in favor of testing and two were
identified against testing. The first theme, “old enough to understand and participate in
decision-making,” was the most common response (41%) and included answers such as “Old
enough to understand the ramifications/consequences,” and “Would want the ability to make an
informed decision and to be able to manage the consequences mentally and physically.” The
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second most common theme was to allow for earlier monitoring of symptoms and tumor
markers (14%) and for increased knowledge and planning (14%), including educating local
physicians and planning for an appropriate time for treatment. The theme “personal and family
experience” (11%) included respondents who selected an age based on when signs of MEN1
first began in their family. Several respondents (6%) who selected a younger age for testing did
so to allow the child to accept the diagnosis as part of their normal life, while another 6% who
selected older ages acknowledged the benefits of family planning with a diagnosis. Five
percent felt genetic testing should be done early because symptoms have been reported in very
young children. Three percent of respondents identified psychological benefits from predictive
testing, such as reassurance from a negative test result. Only two respondents (3%) stated they
selected an ideal age based on local physician recommendations. Several participants
identified negative outcomes of genetic testing as reasons for delaying or never having genetic
testing. These included psychological concerns at a young age when there is little or no risk
(6%) and fears about insurance discrimination (5%). Although all of these reasons were
selected by multiple participants, they were often identified at different times in a child’s life.
Figure 1 shows the distribution of reasons for and against genetic testing at various points in a
child’s life.
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Table 16. Reasons for and Against Genetic Testing*
Reasons for genetic testing
Old enough to understand and participate in decision
making
Earlier monitoring
Allows for increased knowledge and planning
Based on personal or family experience with MEN1
Family Planning
Easier to accept as part of normal life
Could happen at any age
Psychological Benefits
Local recommendations
Reasons against genetic testing
Psychological Concerns
Avoid insurance discrimination
*Answers are not mutually exclusive

41%
14%
14%
11%
6%
6%
5%
3%
3%
6%
5%
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Figure 1. Distribution of Reasons for and Against Genetic Testing Across Age Groups

48

Discussion
Most published literature about genetic testing in minors are expert opinions from
ethicists and although opinions about predictive genetic have been studied in a few other
genetic syndromes [59] [60] [62] [64] [66], no studies have examined this question specifically
in MEN1. This study sought to determine the attitudes about predictive MEN1 genetic testing
in those at risk of having a child with MEN1. This study was exploratory in nature and opens
up several possibilities for future studies and avenues for genetic counseling.
Overall, participants in this study seem to favor genetic testing in minors. Of those who
gave specific ages or age ranges, only seven favored delaying testing until after age 18. The PTAS is a relatively new scale that was previously validated in a population at high risk for a
BRCA mutation [76]. Participants in our study had higher scores for each factor and for total
P-TAS scores than participants in this original study. This is most likely attributable to the
later age of onset of BRCA-related cancers, which almost never present in minors. The fact
that participants have relatively high P-TAS scores demonstrates that both affected participants
and their partners have opinions about genetic testing more similar to a young onset condition
instead of an adult onset condition.
Respondents’ age at the time of study completion was found to be a predictor for
attitudes about genetic testing in most of the completed analyses with older participants more
likely to favor postponing genetic testing until children are older. Older patients may be more
likely to have experienced the effects of MEN1 for longer periods of time either in themselves
or in their families. They may also be more aware of the long-term psychological effects that
come from aging with MEN1, having been diagnosed and adjusted to the diagnosis themselves.
Prior to the availability of MEN1 genetic testing, diagnoses were made on a clinical basis.
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With advances in genetic technology, this younger generation of at risk individuals will be the
first to have predictive testing available to them. Therefore, older participants may also be
drawing on their own experiences with genetic testing when considering the most appropriate
age for predictive testing. It is also likely that younger participants may have benefitted from
earlier genetic testing and/or medical surveillance than older participants, and this might be
influencing their opinions about the ideal age to have genetic testing.
Reasons given for genetic testing at an older age seemed to be strongly focused on
psychological reasons, including the age at which the child can understand and participate,
knowledge and planning, and family planning. On the other hand, many participants who
favored younger ages for testing, including at birth, early childhood and childhood, found the
perceived medical benefits of testing to be the predominant factor in their decision making
about the ideal age to test, which is consistent with previous findings in the literature [52] [53]
[54] [55]. A second predictor, knowledge of MEN1 genetics, suggests that patients with a
better understanding of MEN1 favor genetic testing in minors. This may also suggest that
patients with increased knowledge scores may be more focused on these medical effects and
the opportunity for increased screening over the psychological concerns.
A third predictor for opinions about genetic testing was the number of affected relatives
in a family. Participants with two or more affected relatives were also more likely to favor
genetic testing in minors. Although this variable fell out of significance during the multivariate
analysis, it does point towards a possible trend in family history and suggests that increased
exposure throughout a family may be contributing to opinions favoring a younger age for
genetic testing. Because no other family history variables were found to be significant
predictors, this is an area that may benefit from future research specifically focused on the
impact of family history on age of genetic testing.
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Finally, decisional balance was consistently found to be a strong predictor of
preferences for genetic testing at a younger age. As part of the transtheoretical model, the
decisional balances aims to place participants along a spectrum of stage of change related to a
health behavior, in this case genetic testing in minors. Participants who perceive the cons as
outweighing the pros are less likely to have achieved the action stage of state of change [78]. It
would be expected that parents who place a greater emphasis on the positives of genetic testing
would be more likely to favor genetic testing in minors and/or pursue genetic testing in their
own children, if possible. In fact, participants in this study seemed to have predominantly
positive attitudes about genetic testing with a positive association towards testing in minors and
ideal age less than 14 years. Additionally, a trend appears to be emerging between participants
who have had a child tested for MEN1 and overall P-TAS scores. This might indicate that
participants who are in favor of genetic testing in minors are truly having their child tested for
MEN1 or encouraging their adult children to do so.
Interestingly, this study also identified several factors that do not predict opinions about
genetic testing. Personal medical history does not have a significant impact on opinions about
testing. The reported MEN1-specific medical history of this study population is typical of
individuals with MEN1 reported in the literature, including tumor prevalence and age of
diagnosis [1] [5] [6] [38]. The high penetrance of MEN1-related tumors is also evident given
that all but one affected participants reported a history of at least one tumor type. No clear
pattern emerged between personal medical factors and attitudes for genetic testing suggesting
that opinions vary across patients with MEN1 diagnosed at all ages and with differing degrees
of severity.
Additionally, MEN1-related stress (measured with the Impact of Event scale and
perceived severity of disease) does not appear to impact opinions about predictive MEN1
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genetic testing. Although responses appeared to suggest high levels of MEN1-related stress
with nearly half of participants scoring in the moderate to severe range for IES and most
patients selecting “greatly” for perceived disease severity in the family, neither appeared to
predict attitudes about predictive genetic testing in minors. Several studies have examined
levels of stress and anxiety and the resulting willingness to seek out medical treatment or
genetic testing. Many have shown that patients with high levels of anxiety often seek out
frequent medical advice and reassurance [79] [80]. However, other studies have suggested that
those at a highest risk or who have already begun to show symptoms are also likely to avoid
medical care or postpone presenting to a doctor for fear of the emotional repercussions of a
diagnosis or genetic testing [81] [82]. Therefore, it is possible that patients with higher IES
scores and perceived severity may act in either way with regards to seeking out genetic testing
for themselves or their children.
As an exploratory study, it is particularly interesting to note the reasons that participants
provided for selecting specific ideal ages for MEN1 genetic testing. With certain exceptions,
psychological effects seem to be a driving factor in choosing later ages for genetic testing,
while perceived medical benefits seem to be driving factors at a younger age. A handful of
patients selected multiple ages that often varied significantly. For example, one participant
selected ages 10-12 based on the medical effect it can have during the teenage years but also
selected 25 years and older because of the potential difficulty of obtaining health insurance.
These varied responses further emphasize the lack of clear consensus for when testing should
be performed and also highlight the idea that patients views may be highly conflicted.
Several of the reasons provided in response to this questionnaire matched opinions and
concerns expressed in the literature. The most common reason cited was an age at which
children can understand the implications of genetic testing. This is a sentiment that mirrors
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opinions in professional statements about genetic testing in minors for conditions of unknown
significance, which emphasize the importance of involving the child and family in the decision
making process [50] [51]. Several authors who support testing at a young age indicated that it
would give the child time to accept the diagnosis and adjust to it being part of their everyday
life [54]. This sentiment was echoed by roughly 6% of participants in this study. Other
responses pointed out the enormous psychological burden that could be placed on a child if the
test was positive, years before they may begin to show symptoms. This concern has also been
addressed by authors exploring the potential impacts on children [52] [53] [57]. Thus, this
study exemplifies the varying opinions about the psychological impact of genetic testing and
adds data to the ongoing debate about the psychological effects of genetic testing in minors.
Only two participants selected local physician recommendations as their reason for the
most appropriate age for genetic testing. Of those who selected local recommendations as a
reason for genetic testing, one selected age 5 while the other selected age 10. This again
underscores the lack of a clear consensus about the appropriate age for testing. However, the
low identification with this reason also demonstrates that what guidelines do exist are either not
being expressed to patients and their families, or that patients are forming their own opinions
based on additional factors and their own experiences with MEN1.
Fear of insurance discrimination was listed as a major reason against genetic testing,
however only cited by a minority of participants. Interestingly, many of the participants who
cited this reason were from the UK and stated that it wasn’t a concern within the UK, but it
would be if they lived in a country without universal healthcare. Unlike the US, the UK has a
universal health care system funded by the National Health Service (NHS). Health insurance is
guaranteed to every citizen to cover medical care from primary physicians as well as
specialists. However many citizens also opt to purchase private medical insurance[83]. In
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2009, the Genetic Information Non-discrimination Act [84] was enacted in the United States
and prohibits health insurance companies and employers from discriminating or denying
coverage based on the results of a genetic test. However, this act does not extend to life
insurance or long-term disability insurance. The possibility of genetic discrimination is less
significant in countries with a universal health care system. Although there is currently no law
in the United Kingdom that mirrors GINA, several interest groups have been created to monitor
the progression of genetic testing and its impact on health insurance. A set of moratoriums
have been put in place that prohibit insurance companies from raising premiums based on
genetic test results [83]. Concern about insurance discrimination has frequently been cited by
patients as a limitation for genetic testing in general [85] [86] and many participants in this
study were likely tested prior to the initiation of any protective laws, particularly in the United
States. It is unclear to what extent the study participants knew about anti-genetic
discrimination laws. It may be that some individuals would be reassured if they knew about
laws such as GINA which could change their opinion about genetic testing. Indeed, several
individuals had stated that they were not sure if any anti-discrimination laws had been passed.
Alternately, it may be that people are not reassured that GINA will actually help to protect
them and their family members. With the implementation of these laws and other protective
measures, it will be interesting to monitor the uptake of genetic testing and see if it alters
opinions about genetic testing in minors.
Strengths of Study
Very few studies have investigated the psychological state of patients with MEN1. This
study is the first of its kind to investigate opinions about predictive genetic testing in minors.
Considering the rarity of MEN1, this was a large sample size that included opinions from
around the world. This allowed for opinions from various backgrounds and multiple health
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care systems. Additionally, a strength of this study is that it looked directly at the opinions of
those at risk of having a child with MEN1 and incorporates responses from both affected
participants and co-parents.
Another strength of this study is that most measures used are validated survey tools.
The Impact of Event scale is a frequently used measure for post-traumatic stress disorder and
the decisional balance has been used to measure stage of change. The Pediatric Testing
Attitudes Scale is a relatively new measure that is expected to be used more often in future
studies about genetic testing in minors. The use of validated study measures in this study
strengthens confidence in the results.
Limitations and Future Studies
The major limitation of this study is that it was a self-administered questionnaire. As
such, all medical and family data were self-reported and could not be verified, and the accuracy
of the diagnosis of MEN1 could not be assessed in participants recruited from the Internet.
However, in reviewing the reported medical histories, all participants were typical of MEN1
patients reported in the literature. Additionally, participants were given the option to skip any
questions with which they were uncomfortable, resulting in missing data. Our study was
administered to any patient with a positive genetic test result and their spouses or long-term
partners. This sample included both patients with and without children. Therefore, some
patients were asked to imagine how they would feel about their hypothetical children, which
can be difficult for some patients to consider.
Although our sample size was large for the condition, it was still a small sample size
from a statistical perspective. Clear trends were evident in the data analysis; but future studies
may be able to elucidate further patterns related to a participant’s opinions about predictive
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genetic testing. Because patients and spouses may have some correlation, a generalized linear
mixed model was used for data analysis. However, it is reasonable to assume that spouses may
have an influence on each other’s opinions that could not be captured in the data analysis.
As understanding of MEN1 and cancer genetics continues to grow and screening
technologies improve, it will be important to continually reconsider the most appropriate age
for MEN1 genetic testing. Currently, data into the psychological impact of MEN1 is lacking
and further studies may help to elucidate the most important issues for patients living with
MEN1. Further studies investigating the opinions of health care professionals and how they
counsel families about predictive genetic testing may help to improve guidelines for the most
appropriate age for genetic testing. Studies about patients who have had predictive genetic
testing themselves may also shed more light on the long-term psychosocial effects, as this will
likely be the first generation to have access to predictive genetic testing.
Conclusions and Implications
Our initial hypotheses were that there would be a significant difference between
affected participants and spouses and that age of diagnosis would have an impact on the
preferred age of predictive testing. While we did not find either of these to be true, we did find
several interesting trends. The most significant predictors of favoring genetic testing in minors
are younger current age, increased knowledge, two or more affected relatives, and a positive
decisional balance. Overall, it was clear that most patients and their spouses felt that MEN1
should be addressed earlier than adult-onset conditions and rather as a syndrome with unknown
medical significance at a younger age. Specific considerations for testing in younger children
focused primarily on the perceived medical benefits, whereas participants who selected older
ages in minors were focused primarily on the psychosocial impacts of genetic testing. These
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findings will have several implications for genetic counseling for families at risk of having a
child with MEN1. Although this study was not able to elucidate a single age at which genetic
testing would be most appropriate, the results of this study may help patients consider multiple
viewpoints which may help them determine which factors are most important to them and their
families. When discussing genetic testing with patients, it may also be worthwhile to discuss
reasons other families have expressed for pursuing genetic testing in children. Among the
various responses given, many participants expressed that it was an individual decision for each
child and parent involved. Therefore, in selecting the most appropriate age for their child to be
tested, parents will likely have the clearest ideas about when their child will be able to
understand and deal with the results of a positive genetic test.
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APPENDIX A. INVITATION LETTER
Clinical Cancer Genetics Program
T 713-563-1908 F 713-745-1921
Unit 444
1400 Hermann Pressler Dr
Houston, TX 77030-4008

Date: December 7, 2011
Name:
Address:
Dear Ms./ Mr. <Name>:
We are writing to thank you for your continued participation in our research involving MEN1
and to let you know about a new opportunity. We would like to invite you to take part in a
research study entitled Parental Attitudes of Predictive MEN1 Genetic Testing in Minors. We
are interested in learning about your experiences and feelings towards MEN1 genetic testing
in healthy children.
We are inviting you to participate because you, your spouse/partner, or a family member was
seen for MEN1 at M. D. Anderson Cancer Center. As you know, MEN1 is a rare hereditary
condition that increases cancer risk and can be passed on to children. The ideal age for
genetic testing in minors who have no symptoms is unclear. We are interested in learning how
families with MEN1 feel about having their children genetically tested for MEN1. Participation
in this research study is voluntary and involves completing the enclosed survey. The survey
should take about 15-20 minutes to complete and there is no cost to participate.
Although your participation in this project may not have direct benefit to you, it will help
researchers, doctors and genetic counselors better understand the needs of families with
children at risk for MEN1. Some of the questions may be upsetting and you do not have to
answer them. If you decide to participate in the study, it is very important that you answer as
completely as you can; please feel free to add comments or questions on the survey and we
will do our best to respond.
If you would like to participate in this study, please complete the questionnaire that is included
in this packet and return it to us in the pre-paid addressed envelope. Patients who have been
diagnosed with MEN1, please complete the white survey. Spouses or partners of persons
with MEN1 please complete the yellow survey. We are interested in responses from both
patients and spouses but responses will still be included even if only one person is available to
participate.
If you prefer the online survey, please go to http://www.surveymonkey.com/s/MEN1inminors
and follow the instructions. You will need to enter your ID user number, which is <insert ID #>.
The online survey has the same questions as the one included in this packet and was created
using a professional account on Survey Monkey, which is a confidential survey making tool.
Your responses will be strictly confidential and will only be shared with study staff.
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Clinical Cancer Genetics Program
T 713-563-1908 F 713-745-1921
Unit 444
1400 Hermann Pressler Dr
Houston, TX 77030-4008

At the end of the survey, there is a place to write your name and telephone number if you
are willing to be contacted with questions about any of your responses. If you have any
friends or relatives you think would be interested in participating in the study, a space is
available for their contact information so we can send them a copy of this letter as well.
Providing contact information is optional, and your name will not be linked with your survey
responses, if provided.
Completion of this survey is optional and confidential. Due to the anonymous nature of the
study, questionnaires will not be able to be withdrawn once they have been submitted. If you
have any questions or would like more information please contact, the Clinical Cancer
Genetics Program or your genetic counselor at (713) 745-7391 or e-mail
ccg@mdanderson.org.
Thank you very much for considering this invitation to participate in our study.
Sincerely,

Katie Rock, BA
Genetic Counseling Intern

Thereasa Rich, MS, CGC
Genetic Counselor

Elizabeth Grubbs, MD
Assistant Professor
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APPENDIX B: AFFECTED PARTICIPANT QUESTIONNARIE
Please fill out this survey if YOU have been diagnosed with MEN1

ID#

I have read the description of the study, and I have decided to participate in the
research project described here. I understand that I may refuse to answer any (or all)
of the questions at this or any time. I understand that my decision about participating
in this study or answering questions will not affect the care or services that I receive at
M. D. Anderson Cancer Center.
During the course of this study, the research team at The University of Texas M. D.
Anderson Cancer Center will be collecting information about me that they may share
with health authorities, study monitors who check the accuracy of the information, and
individuals who put all the study information together in report form. Information that
could identify me personally will not be made public. By answering the questions, I am
providing authorization for the research team to use and share my information at any
time. If I do not want to authorize the use and disclosure of my information, I may
choose not to answer these questions. There is no expiration date for the use of this
information as stated in this authorization.
Completion of this survey is optional and confidential. Due to the anonymous nature
of the study, questionnaires will not be able to be withdrawn once they have been
submitted. If you have any questions or would like more information please contact,
the Clinical Cancer Genetics Program or your genetic counselor at 713-745-7391 or email ccg@mdanderson.org. For information on the Notice of Privacy Practices, please
call 713-792-2933.

Attitudes Toward MEN1 Genetic Testing in Minors Survey
Instructions: We are interested in learning about your attitudes toward MEN1 genetic
testing for healthy children who are under the age of 18. As you may know, the best
age for healthy children to undergo MEN1 genetic testing is unknown due to several
medical, social, and psychological reasons. We wish to learn about your experience
and attitudes toward such testing.
Part 1: The following are questions about YOU.
1. What is your age: ________
2. What is your gender?
Male
3.

Female

Where do you currently live?

State: ______________ Country:_____________

4. What is your marital status?
Single

Married/Long Term Partner

Separated

Divorced

Widowed

5. What is the highest grade or level of schooling you completed?
Some high school
High school graduate
Some college

College graduate (4 Year Degree)
Associate’s degree
Upper-level degree
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Please fill out this survey if YOU have been diagnosed with MEN1

ID#

6. What is your current occupational status
Employed (Full Time)

Homemaker

Employed (Part Time)

Student

Unemployed (Not seeking a job)

Retired

Unemployed (Seeking a job)
7. What is your (combined) annual household income?
Less than $25,000

$50,000 - $75,000

$25,000 - $50,000

More than $75,000

8. Please check any of the following you’ve been diagnosed with and write the age you were
diagnosed:
Parathyroid gland tumor (hyperparathyroidism); Age diagnosed: _____
Pituitary gland tumor (for example, prolactinoma); Age diagnosed: ____
Pancreatic/stomach/intestinal tumor (for example, gastrinoma, neuroendocrine tumor);
Age diagnosed: _____
Has this tumor spread (metastasized)? Yes

No

9. Have you had genetic testing for MEN1?
Yes

No

If yes, was a mutation found (was the test positive)? Yes

No

10. At what age did you first find out you had MEN1 (if you are not sure, just give your best guess)?
________
11. How many members of your family also have been diagnosed with MEN1?
None
1-2
3-4
5 or more
12. Do you have any relatives who have died from complications of MEN1?
Yes

No

If yes, how old were they when they died? __________
13. How severely do you feel MEN1 has affected your family’s health and well-being? (Please
circle a number on the scale below).
Not at all
1

Somewhat
2

3

Greatly
4

5
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Please fill out this survey if YOU have been diagnosed with MEN1

ID#

14. Has anyone in your family been diagnosed with an MEN1-related tumor before 18 years of
age?
Yes

No

If yes, how old were they? _____
If yes, how are they related to you (for example, sister, cousin, etc.)?
_____

15. Do you have children?
Yes – if yes, please continue to part 2
No – if no, please skip part 2, and continue to part 3
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Please fill out this survey if YOU have been diagnosed with MEN1

ID#

Part 2: Please tell us about each of your children, including your adult children,
if applicable
(please only include children who are biologically related to you):

How old
is this
child?

Child
1

Child
2

Child
3

Child
4

Child
5

Child
6

Gender

Has this child
been diagnosed
with any MEN1related tumors?
If yes, how old
were they when
they were first
diagnosed?

Male

Yes

No

Female

Age Diagnosed:

Male

Yes

Female

Age Diagnosed:

Male

Yes

Female

Age Diagnosed:

Male

Yes

Female

Age Diagnosed:

Male

Yes

Female

Age Diagnosed:

Male

Yes

Female

Age Diagnosed:

No

No

No

No

No

Has this child
had MEN1
genetic testing?
If yes, how old
were they when
they were
tested?
Yes

No

Age Tested:
Result:
Yes

No

Age Tested:
Result:
Yes

No

Age Tested:
Result:
Yes

No

Age Tested:
Result:
Yes

No

Age Tested:
Result:
Yes

No

Age Tested:
Result:

Have you shared
your family’s
diagnosis of
MEN1 with this
child?
If yes, how old
were they when
you told them?
Yes

No

Age Told:
Yes

No

Age Told:
Yes

No

Age Told:
Yes

No

Age Told:
Yes

No

Age Told:
Yes

No

Age Told:

If you have more than 6 children, please use the back of this survey to tell us about
them.
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Please fill out this survey if YOU have been diagnosed with MEN1
ID#

Part 3: The following questions are intended to find out what people know about
cancer and genetic testing so that we can improve our educational efforts. This
is not a test. We are simply interested in finding out what the general level of
knowledge is regarding these topics. Please indicate whether you think each
statement is true or false, or if you don't know.
16

An altered MEN1 susceptibility gene can be
inherited from either parent.

True

False

Unsure

17

If Lisa looks more like her mother than her
father, she has probably received more of her
genetic information from her mother.

True

False

Unsure

18

A person who carries an altered MEN1
susceptibility gene will definitely develop
features of MEN1 in his or her lifetime.

True

False

Unsure

19

Susan is the first born in her family. Her
mother, who has MEN1, was also the first
born. Thus, Susan has a higher risk of
developing MEN1 than her younger brothers
and sisters.

True

False

Unsure

20

Rick has had genetic testing for an MEN1
gene alteration that was found in his family.
His results were negative; therefore, he is not
at increased risk to develop features of
MEN1.

True

False

Unsure

21

Kelly has had genetic testing for an MEN1
gene alteration that was found in her family.
Her results were negative; therefore, her
children are not at risk to inherit MEN1 from
her.

True

False

Unsure

22

John’s father has an altered MEN1 gene.
The chance that John has inherited this gene
alteration is 50% or 1 in 2.

True

False

Unsure

23

Once a gene alteration has been detected in
a person with MEN1, their family members
can be tested for the gene alteration to know
for certain whether or not they also have
MEN1.

True

False

Unsure
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Please fill out this survey if YOU have been diagnosed with MEN1

ID#

Part 4. Please think about your experience with MEN1 in your family. Please
indicate how frequently each comment was true for you during the past seven
days.
Not at
all

Rarely

Some
times

Often

24

I thought about it when I didn’t mean to.

1

2

3

4

25

I avoided letting myself get upset when I
thought about it or was reminded of it.

1

2

3

4

26

I tried to remove it from my memory.

1

2

3

4

27

I had trouble falling asleep or staying asleep
because of pictures or thoughts about it that
came into my mind.

1

2

3

4

28

I had waves of strong feelings about it.

1

2

3

4

29

I had dreams about it.

1

2

3

4

30

I stayed away from reminders of it.

1

2

3

4

31

I felt as if it hadn’t happened to me or it wasn’t
real.

1

2

3

4

32

I tried not to talk about it.

1

2

3

4

33

Pictures about it popped into my mind.

1

2

3

4

34

Other things kept making me think about it.

1

2

3

4

35

I was aware that I still had a lot of feelings
about it, but I didn’t deal with them.

1

2

3

4

36

I tried not to think about it.

1

2

3

4

37

Any reminder brought back feelings about it.

1

2

3

4

38

My feelings about it were kind of numb.

1

2

3

4
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Please fill out this survey if YOU have been diagnosed with MEN1

ID#

Part 5: The following questions ask about your personal feelings about genetic
testing in healthy minors (in other words, individuals with no medical conditions
who are younger than age 18). Please indicate your agreement with each of the
following statements using the scale below.
Strongly
Disagree

Disagree

Neither
Agree
nor
Disagree

Agree

Strongly
Agree

Children under age 18
should be given the
39 opportunity to be genetically
tested for the MEN1gene
alteration

1

2

3

4

5

40

Parents should decide if
their children are allowed to
have an MEN1 genetic test
or not, even if a doctor
disagrees

1

2

3

4

5

41

Even though some of the
conditions associated with
MEN1 may not affect
people until they reach
adulthood, children should
still be offered MEN1
genetic testing

1

2

3

4

5

42

Children should be involved
in making the decision
about whether or not they
have MEN1 genetic testing

1

2

3

4

5

43

I am in favor of MEN1
genetic testing for children

1

2

3

4

5

44

If children are tested and
they turn out to carry an
MEN1 gene alteration (that
is, they test positive), they
should be told about their
test result immediately

1

2

3

4

5
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45

Even if there is no known
prevention for the
conditions associated with
MEN1, children should be
offered MEN1 genetic
testing

1

2

3

4

5

46

If children are tested and
they turn out to carry a
MEN1 gene alteration (that
is, they test positive), then
this information should be
shared with the child’s
pediatrician

1

2

3

4

5

47

I want my child to have
genetic testing for MEN1
before age 18

1

2

3

4

5

48

If children are tested and
they turn out not to carry an
MEN1 gene alteration (that
is, they test negative), they
should be told about their
test result immediately

1

2

3

4

5

49

The benefits of children
participating in MEN1
genetic testing outweigh the
risks

1

2

3

4

5
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Please fill out this survey if YOU have been diagnosed with MEN1

ID#

Part 6: The following list includes reasons some people give for wanting or not wanting to
have their child have genetic testing. Please indicate how important you feel each of the
following is in making a decision to have MEN1 genetic testing for your child using the 1-5
point scale.
Not
Importa
nt

Slightly
Importa
nt

Somewh
at
Important

Impor
tant

Very
Importa
nt

50

I would be relieved to know my child
did not have MEN1

1

2

3

4

5

51

My own experience with MEN1 makes
me more concerned about my child’s
risk for the disease

1

2

3

4

5

52

I’m afraid I would get too upset

1

2

3

4

5

1

2

3

4

5

53

I / My child could plan for the future

54

I’m afraid my child would get too upset

1

2

3

4

5

55

I am concerned that having the test
might cause problems with my child’s
insurance

1

2

3

4

5

56

I am concerned about my family’s
reactions

1

2

3

4

5

57

I want to learn whether my child is at
risk for MEN1

1

2

3

4

5

58

I am worried about how it would affect
my relationship with my child

1

2

3

4

5

59

I’m not sure if the genetic test is
accurate

1

2

3

4

5

60

Something could be done to improve
my child’s health

1

2

3

4

5

61

I have a responsibility to let my child
know if he/she has MEN1

1

2

3

4

5

62

I just want to know

1

2

3

4

5

63

The cost of genetic testing is too
expensive for my family to afford

1

2

3

4

5
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Please fill out this survey if YOU have been diagnosed with MEN1

ID#

64. What do you feel is the ideal age for an individual to have MEN1 genetic testing? Why
did you choose this age?
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Please fill out this survey if YOU have been diagnosed with MEN1

ID#

The following questions are optional:
Please indicate if we may contact you by phone with any follow up questions:
Yes

No

Name: __________________________________
Phone Number: __________________________
We would like to include as many people as possible in this survey. Individuals with
MEN1 and their spouses/partners are eligible. Please tell us about any friends or
relatives who may be interested in participating in our study:
Name: _____________________________________
Relationship to you: _________________________
Email: _____________________________________
Phone: ____________________________________
Address: ___________________________________
___________________________________
___________________________________
Name: _____________________________________
Relationship to you: _________________________
Email: _____________________________________
Phone: ____________________________________
Address: ___________________________________
___________________________________
___________________________________

Thank you very much for completing this questionnaire. The information you have
provided has been very helpful and we appreciate your thoughtful answers.
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APPENDIX C: SPOUSE/PARTNER QUESTIONNAIRE
Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1

ID#

I have read the description of the study, and I have decided to participate in the
research project described here. I understand that I may refuse to answer any (or all)
of the questions at this or any time. I understand that my decision about participating
in this study or answering questions will not affect the care or services that I receive at
M. D. Anderson Cancer Center.
During the course of this study, the research team at The University of Texas M. D.
Anderson Cancer Center will be collecting information about me that they may share
with health authorities, study monitors who check the accuracy of the information, and
individuals who put all the study information together in report form. Information that
could identify me personally will not be made public. By answering the questions, I am
providing authorization for the research team to use and share my information at any
time. If I do not want to authorize the use and disclosure of my information, I may
choose not to answer these questions. There is no expiration date for the use of this
information as stated in this authorization.
Completion of this survey is optional and confidential. Due to the anonymous nature
of the study, questionnaires will not be able to be withdrawn once they have been
submitted. If you have any questions or would like more information please contact,
the Clinical Cancer Genetics Program or your genetic counselor at 713-745-7391 or email ccg@mdanderson.org. For information on the Notice of Privacy Practices, please
call 713-792-2933.

Attitudes Toward MEN1 Genetic Testing in Minors Survey
Instructions: We are interested in learning about your attitudes toward MEN1 genetic
testing for healthy children who are under the age of 18. As you may know, the best
age for healthy children to undergo MEN1 genetic testing is unknown due to several
medical, social, and psychological reasons. We wish to learn about your experience
and attitudes toward such testing.
1.

Part 1: The following are questions about YOU.
What is your age: ________

2. What is your gender?
Male

Female

3. Where do you currently live?

State: ______________ Country:_____________

4. What is your marital status?
Single

Married/Long Term Partner

Separated

Divorced

Widowed

5. What is the highest grade or level of schooling you completed?
Some high school

College graduate (4 Year Degree)

High school graduate

Associate’s degree

Some college

Upper-level degree
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Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1

ID#

6. What is your current occupational status?
Employed (Full Time)

Homemaker

Employed (Part Time)

Student

Unemployed (Not seeking a job)

Retired

Unemployed (Seeking a job)
7. What is your (combined) annual household income?
Less than $25,000

$50,000 - $75,000

$25,000 - $50,000

More than $75,000

8. Please check all of the following that apply to you:
I am currently married to someone who has MEN1.
I used to be married/partner to someone who has MEN but we are now separated.
I have biological children who have MEN1, or who are at risk to inherit MEN1
I have step children/adopted children who are at risk to inherit MEN1
9. How many members of your family or your spouse’s/partner’s family have been diagnosed
with MEN1?
None
1-2
3-4
5 or more
10. Do you or your spouse/partner have any relatives who have died from complications of
MEN1?
Yes

No

If yes, how old were they when they died? __________

11. How severely do you feel MEN1 has affected your or your spouse’s family’s health
and well-being? (Please circle a number on the scale below).
Not at all

Somewhat

1

2

3

Greatly
4

5

12. Has anyone in your family been diagnosed with an MEN1-related tumor before 18 years of
age?
Yes

No

If yes, how old were they? _____
If yes, how are they related to you (for example, sister, cousin,
etc.)? _____
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Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1

ID#

Part 2: The following questions are intended to find out what people know about
cancer and genetic testing so that we can improve our educational efforts. This
is not a test. We are simply interested in finding out what the general level of
knowledge is regarding these topics. Please indicate whether you think each
statement is true or false, or if you don't know.
13

An altered MEN1 susceptibility gene can be
inherited from either parent.

True

False

Unsure

14

If Lisa looks more like her mother than her
father, she has probably received more of her
genetic information from her mother.

True

False

Unsure

15

A person who carries an altered MEN1
susceptibility gene will definitely develop
features of MEN1 in his or her lifetime.

True

False

Unsure

16

Susan is the first born in her family. Her
mother, who has MEN1, was also the first
born. Thus, Susan has a higher risk of
developing MEN1 than her younger brothers
and sisters.

True

False

Unsure

17

Rick has had genetic testing for an MEN1
gene alteration that was found in his family.
His results were negative; therefore, he is not
at increased risk to develop features of
MEN1.

True

False

Unsure

18

Kelly has had genetic testing for an MEN1
gene alteration that was found in her family.
Her results were negative; therefore, her
children are not at risk to inherit MEN1 from
her.

True

False

Unsure

19

John’s father has an altered MEN1 gene.
The chance that John has inherited this gene
alteration is 50% or 1 in 2.

True

False

Unsure

20

Once a gene alteration has been detected in
a person with MEN1, their family members
can be tested for the gene alteration to know
for certain whether or not they also have
MEN1.

True

False

Unsure
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Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1

ID#

Part 3. Please think about your experience with MEN1 in your family. Please
indicate how frequently each comment was true for you during the past seven
days.
Not at
all

Rarely Sometimes Often

21

I thought about it when I didn’t mean to.

1

2

3

4

22

I avoided letting myself get upset when I
thought about it or was reminded of it.

1

2

3

4

23

I tried to remove it from my memory.

1

2

3

4

24

I had trouble falling asleep or staying
asleep because of pictures or thoughts
about it that came into my mind.

1

2

3

4

25

I had waves of strong feelings about it.

1

2

3

4

26

I had dreams about it.

1

2

3

4

27

I stayed away from reminders of it.

1

2

3

4

28

I felt as if it hadn’t happened to me or it
wasn’t real.

1

2

3

4

29

I tried not to talk about it.

1

2

3

4

30

Pictures about it popped into my mind.

1

2

3

4

31

Other things kept making me think about
it.

1

2

3

4

32

I was aware that I still had a lot of
feelings about it, but I didn’t deal with
them.

1

2

3

4

33

I tried not to think about it.

1

2

3

4

34

Any reminder brought back feelings
about it.

1

2

3

4

35

My feelings about it were kind of numb.

1

2

3

4
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Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1

ID#

Part 4: The following questions ask about your personal feelings about genetic
testing in healthy minors (in other words, individuals with no medical conditions
who are younger than age 18). Please indicate your agreement with each of the
following statements using the scale below.
Strongly
Disag
Neither
Agr Strongly
Disagree
ree
Agree nor
ee
Agree
Disagree
Children under age 18
should be given the
36
opportunity to be
1
2
3
4
5
genetically tested for the
MEN1gene alteration
Parents should decide if
their children are allowed
37 to have an MEN1 genetic
1
2
3
4
5
test or not, even if a
doctor disagrees
Even though some of the
conditions associated with
MEN1 may not affect
people until they reach
38
1
2
3
4
5
adulthood, children should
still be offered MEN1
genetic testing
Children should be
involved in making the
39 decision about whether or
1
2
3
4
5
not they have MEN1
genetic testing
I am in favor of MEN1
40
1
2
3
4
5
genetic testing for children
If children are tested and
they turn out to carry an
MEN1 gene alteration
41 (that is, they test positive),
1
2
3
4
5
they should be told about
their test result
immediately
Even if there is no known
prevention for the
conditions associated with
42
1
2
3
4
5
MEN1, children should be
offered MEN1 genetic
testing
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43

44

45

46

If children are tested and
they turn out to carry a
MEN1 gene alteration
(that is, they test positive),
then this information
should be shared with the
child’s pediatrician
I want my child to have
genetic testing for MEN1
before age 18
If children are tested and
they turn out not to carry
an MEN1 gene alteration
(that is, they test
negative), they should be
told about their test result
immediately
The benefits of children
participating in MEN1
genetic testing outweigh
the risks

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5
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Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1

ID#

Part 5: The following list includes reasons some people give for wanting or not wanting to have
their child have genetic testing. Please indicate how important you feel each of the following is
in making a decision to have MEN1 genetic testing for your child using the 1-5 point scale.

Not
Slightly
Somewh
Importan
Importan Importan
at
t
t
t
Important

Very
Importa
nt

47

I would be relieved to know my child
did not have MEN1

1

2

3

4

5

48

My own experience with MEN1
makes me more concerned about my
child’s risk for the disease

1

2

3

4

5

49

I’m afraid I would get too upset

1

2

3

4

5

1

2

3

4

5

50

I / My child could plan for the future

51

I’m afraid my child would get too
upset

1

2

3

4

5

52

I am concerned that having the test
might cause problems with my child’s
insurance

1

2

3

4

5

53

I am concerned about my family’s
reactions

1

2

3

4

5

54

I want to learn whether my child is at
risk for MEN1

1

2

3

4

5

55

I am worried about how it would
affect my relationship with my child

1

2

3

4

5

56

I’m not sure if the genetic test is
accurate

1

2

3

4

5

57

Something could be done to improve
my child’s health

1

2

3

4

5

58

I have a responsibility to let my child
know if he/she has MEN1

1

2

3

4

5

59

I just want to know

1

2

3

4

5

60

The cost of genetic testing is too
expensive for my family to afford

1

2

3

4

5
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Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1

ID#

61. What do you feel is the ideal age for an individual to have MEN1 genetic testing?
Why did you choose this age?

78

Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1

ID#

The following questions are optional:
Please indicate if we may contact you by phone with any follow up questions:
Yes

No

Name: __________________________________
Phone Number: __________________________
We would like to include as many people as possible in this survey. Individuals with
MEN1 and their spouses/partners are eligible. Please tell us about any friends or
relatives who may be interested in participating in our study:
Name: _____________________________________
Relationship to you: _________________________
Email: _____________________________________
Phone: ____________________________________
Address: ___________________________________
___________________________________
___________________________________
Name: _____________________________________
Relationship to you: _________________________
Email: _____________________________________
Phone: ____________________________________
Address: ___________________________________
___________________________________
___________________________________

Thank you very much for completing this questionnaire. The information you have
provided has been very helpful and we appreciate your thoughtful answers.
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APPENDIX D: REMINDER LETTER
Clinical Cancer Genetics Program
T 713-563-1908 F 713-745-1921
Unit 444
1400 Hermann Pressler Dr
Houston, TX 77030-4008

Date
Name
Address
Dear Ms./Mr. <Name>:
Over the last several weeks we have tried to contact you at the above address about our study
Parental Attitudes of Predictive MEN1 Genetic Testing in Minors. As of <the date shown at
the top of this letter>, we have not received the questionnaire back from you nor have we
received a refusal to take part in this study. It is possible that you may have sent in your
survey and our records have not been updated yet. If you have already completed the survey,
thank you for your response and please disregard this letter.
We are interested in obtaining information about parental attitudes toward MEN1 predictive
genetic testing in their healthy children. The questions that you will be answering will help the
researchers and physicians to better understand the needs of families with children at risk for
MEN1 and provide the appropriate services. Participation in the study involves completing a
questionnaire.
If you are interested in taking part in this study and have lost the questionnaire, we have
enclosed another copy for your convenience. Patients who have been diagnosed with MEN1,
please complete the white survey. Spouses or partners of persons with MEN1 please
complete the yellow survey. We are interested in responses from both patients and spouses
but responses will still be included even if only one person is available to participate. If you do
not wish to take part in this study, please indicate this and also return the blank questionnaire
to us in the pre-addressed envelope.
If you prefer the online survey, please go to http://www.surveymonkey.com/s/MEN1inminors
and follow the instructions. You will need to enter your ID user number, which is <insert ID#>.
The online survey consists of the same questions as the one that is included in this packet and
was created using a professional account on Survey Monkey, which is a confidential survey
making tool. Your response will be maintained strictly confidential and will only be shared with
study staff.
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Completion of this survey is optional and confidential. Due to the anonymous nature of the
study, questionnaires will not be able to be withdrawn once they have been submitted. If you
have any questions or would like more information please contact, the Clinical Cancer
Genetics Program or your genetic counselor at (713) 745-7391 or e-mail
ccg@mdanderson.org. Thank you very much for considering this invitation to participate in our
study.

Sincerely,
Katie Rock, BA
Genetic Counseling Intern

Thereasa Rich, MS, CGC
Genetic Counselor

Elizabeth Grubbs, MD
Assistant Professor
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APPENDIX E: OPEN ENDED SUREVEY RESPONSES
•

I would say when they are reaching puberty or early teens. I feel that if it is done early
on, i.e. infancy, then it would cause unnecessary heartache when it is important to be
bonding with your child. I also think there is less risk at infancy and younger years of
having complications due to MEN1. I feel at puberty the child is old enough to involve
themselves in whether they want the testing and their maturity level would help them
understand to some extent a very complicated diagnosis.

•

Being a female, I began showing signs around the age of 13 or having female problems,
also they may start to get the mole like spots on the face.

•

8-10

•

1. It could happen at any age. Very concern 2. There is no age of when humans get
MEN1 it just develop in your system. By that time it mite be to late for processes

•

It's a independent decision for each parent. I found out that I had MEN1, back in 1995
when I was 33. My daughter, at the time was 14. I stressed and worried over the fact
that I could of passed the gene onto her. Not knowing was stressful. Finally, in 2003 we
found out that genetic testing was available (here at MDAnderson) my daughter was 22
- We definitely wanted the testing. She was getting married and considering starting a
family, she also wanted to know. Luckily, she was negative to carry for gene. If genetic
testing was available to us back in 1995, we would choose to have her tested.

•

Not sure, depends on maturity of child, but probably 12 or 13 years old. Old enough to
understand ramifications/consequences.
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•

By age 10. So you can start monitoring the markers (calcium, Prolactin, PTH, gastrin,
etc.) if tested positive.

•

I feel a child should be tested as soon as doctor's are confident that results would be
accurate. If there is any chance of change of testing I would have peace of mind in
having a second testing done. I do not feel it is ever too early to be on the lookout for
symptoms with MEN1. As negative result is best, at least with a positive result we can
be more cautious with our children as they mature. Personally I have doubts as to where
I would be now had I not have known about my condition only because of my family
history.

•

I was diagnosed at 34 after pancreatic cancer surgery. My father was diagnosed two
years after me! My twins were very mature at age 14 and we talked about testing and
what it might mean. They both wanted to be tested. They wanted to know the results
whether good or bad. (obviously you would tell them if negative to celebrate and avoid
anxiety.)
I was devastated to find out my boys were positive. They are identical so we knew the
chance that if one was positive, both likely would be.
Since diagnosis, my boys have yearly screening and when one son had a blood sugar
issue, we acted quickly to rule out a PNET.

•

16-18, Most young people, at this age, would have some level of maturity to
understand what genetic testing is and why it might be important for them personally.
They may have seen a grandparent, parent or sibling deal with the presentation of
symptoms or surgery and testing could enhance their knowledge. By this age some
could have had opportunity to study biology and all the new ways technology is
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discovering more specific and accurate health data. Most would have completed puberty
and have some stabilization of hormones.
•

At any age that the child could understand what illness is. That things can go wrong
with your body. That its not your fault.

•

As a parent, I would like to know if son was + or - before puberty onset.
While I realize that some individuals handle information differently, I would like to
start a baseline for certain tests and choose an acceptable monitoring schedule through
pediatrician or other dr. For kids, I do not think it would need to be as frequent as adults
with manifestations. My MEN has been monitored/addressed proactively and as a result
does not impact my life in a major or negative way. I hope the same for my son.
Information allows one to plan…and if necessary anticipate. I prefer to have as much
info as possible. I do not feel that a child (younger than 18) needs to know…unless the
disease manifests itself in some way…and even then some concepts may be beyond
their grasp. My opinion may shift if test results impacted insurance options now or in
future.

•

About age 25 when they are somewhat more mature and can make better decisions
about their lives.

•

17. They should be old enough to handle the results and are still living at home.

•

I wouldn't support the testing for children under 12, but 12-18 is appropriate.
It's an individual choice. If family members exhibit symptoms, the testing may be more
important.

•

13, they will be more understanding
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•

I don't feel the age of the test is as important as when the child is told/explained about
the disease

•

As soon as possible --> had my M EN1 been discovered earlier, it likely would have
resulted in less-invasive surgery. The tumors could have been removed earlier and
saved me a more healthy pancreas.

•

14 - old enough to understand the situation.

•

18 Knowledge is power. Knowledge can overcome fear.

•

14 years of age. They may be able to better understand the ramifications of MEN1
related medical problems.

•

In my family, MEN1 has not been an issue until late teenage years (symptom wise). I
feel during the child's teens would be a good time to test and explain to the child what it
is. I don’t see a sense in putting the stress into a child’s life if there is no preventative
care needed. Once the child knows MEN1 could be a factor in their health they should
be tested. I felt more stress waiting for the test results than I have felt since knowing I
have MEN1. In the end I would like my child to make that decision for herself and
share my experience with her to help her decide.

•

Not qualified to say. I feel it is important to know as soon as possible and educate all
involved including medical professionals.

•

17 yrs old This is an age that a child can become more responsible and able to
understand the diagnosis. The decision can be made in regards to family planning. This
is also the age most of my family began to have symptoms of high calcium and kidney
stones. Therefore, the diagnosis would have been made prior to symptoms and not be an
85

"elephant in the room." It is better to know than to have an unknown hanging over your
head.
•

17 young enough to understand, but old enough to be able to handle the condition.

•

Before the age of 10. My experience was that my hyper-parathyroidism was already
present at age 11. It's also my opinion that if a child is diagnosed younger that they will
accept MEN 1 and the resulting exams/testing as a 'normal' part of their life.

•

I believe that the ideal age for someone to have genetic testing for MEN1 should be
around 6-8 years old. I say that because that is about the time I started being a "sickly"
child and went for years with no answers as to what was going on. I also believe that if
they would have tested me for MEN syndrome when they found my first pituitary tumor
and was on synthoid at the time. Basically, where I come from they have never heard of
such and just kept giving me meds that didn't work and the problems were getting
worse. I have to travel hours to Dallas or Houston to find someone to treat me because
all of the local doctors just look at me and say that I have way too many problems and
am way to complicated.

•

Before 10 - Not Sure Really

•

13..so that as a young adult children can have the pros and cons carefully explained to
them

•

I am not sure there is a good age. Mine was detected by accident I will never know if all
of the pain, anguish and worry has been for nothing. maybe I would have got though to
old age with no problems. Instead I now live in fear. I have had 2 operations in the last
3 years but never had a single symptom. I rarely saw a doctor and thought I was fitter
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than all of my peers leading a physically active lifestyle, never had a day off sick. I
considered I was a particularly optimistic and strong person, I am now in receipt of
councelling. It is known that stress affects the immune system- so is causing stress
going to make the development of tumours more likely? This is a Kafkaresque world. I
wouldn't want to put this onto any one else and certainly not a young person. Should an
easy "cure" be forthcoming of course this changes everything.
•

Would rather treat symptoms then worry about having the genetic mutation. If a family
member is in a research trial that does the testing, then so be it. But once there is a
positive in the family, I don't feel any other family member needs to be genetically
tested. Again it is about treating the symptoms not the genetic test.

•

25. Ideal age to make informed decisions

•

Age 10 because they are old enough to understand but young enough to process the
information for a long time before signs/symptoms. Also, in the rare case the child may
already need treatment at a young age.

•

I am not sure what the ideal age would be.

•

21/22 Except in exceptional circumstances, once adult education is completed

•

5-10 years old. Tumors have been shown to develop this early, so in addition to
psychological benefits of a negative test, one saves money on annual screenings. If
positive, the risks for insurance, etc. seem outweighed. Also, they are old enough to
learn about MEN.

87

•

At birth. Less traumatic for the child (who wont remember having it), and gives parents
options with regard to age to begin screening etc. I have heard that children as young as
5 have shown symptoms

•

10. It seems like a reasonable age for a child to begin to understand the implications of a
genetic test and a genetic disorder.

•

I think a child should be tested whenever their parents think, My son will be tested in
the new year when he reaches 5, and my youngest may get tested before that age. My
eldest is being tested when he turns 5 because it is the recommended age here in the
UK, all of my family history has shown that we suffer with MEN 1 symptoms from an
early age and I think my child has the right to know what may or may not happen in his
life, if the test is positive he will be told when he can understand what it means and he
can make the decisions about the screening. My mother died at the very very early age
of 34 when her children were just 11 and 13, this impacts my decisions also because my
sons both need to understand why their grandma isn't here and also why their mummy is
sometimes in hospital. They deserve to know whether they have MEN regardless of
age.

•

I didnt have a choice at a younger age. the family was unaware of the condition. until
my late 30s at which point I had suffered for years. I was tested positive at 40

•

10 years old

•

16 as i would want them to have the ability to make an informed decision and to be able
to manage the concequences mentally and physically if necessary
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•

Ten years old is the age offered to children in Scotland. I feel this is young enough
unless they show signs of the illness before this age, as they don't really understand
what is going on. Emotionally it is very difficult for them too. My child had a positive
diagnosis at the age of ten and has been quite unwell over the last two years from age 12
to 14. so for me, the genetic testing was important and it now means that my daughter is
kept under medical supervision which puts our minds at ease. Admittedly though she
has found the diagnosis difficult mainly because she has watched myself (her mum),
struggle with the illness since she was little and doesn't want to go through what I am
going though. It scares her about what the future may hold for her.

•

As soon as MEN is known for a parent. It can help in how to approach healthcare. If
there are tumors it is better to find them early.

•

16-

•

I would say 15-18 is a good age, as before that you won't necessarily understand the
condition and it's implications and you also have the emotional maturity to deal with it
(though 15 - 18 can be a testing time anyway!) In addition I would also suggest that
testing before 2 years of age is appropriate too as it means that having the condition is
normal, so no emotional adjustment is needed (if that makes sense).

•

From birth if there is already MEN1 in the family or ASAP if they show any signs

•

10. This is when I developed symptoms

•

If insurance isn't a problem then as early as possible, there are cases of
hyperparathyroidism developing in pre-school children, therefore I feel its important to
start checking early as possible to avoid long term health problems.
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•

The age would depend on the individual's health and ability to understand the issues. If
a child of a parent with MEN1 is unwell with symptoms that could be due to an MEN1
related tumour then this is an argument in favour of doing the test at that point, but if
the child remains healthy, I would think it preferable to wait until the child is able to
participate in such a decision. As children mature intellectually and emotionally
differently, and their family circumstances differ, I think this should be decided on an
individual basis with no prescribed age. In countries other than the UK, the issue of
insurance difficulties would be a strong factor against testing both of minors and adults
(health insurance is universal, free and very comprehensive in the UK - and the test
itself is paid for by the national health service, so this is not a concern in the UK).

•

10, when the child can understand some of it, but before getting to be a teenager when it
became more traumatic

•

I would like to know as soon as a child is born. If the test is positive you can keep a
close eye for any MEN1 symptoms as early as needed to keep the childs health as good
as possible.

•

5 YEARS OLD, BECAUSE YOU CAN EXPLAIN TO THEM WHY THEY ARE
HAVING THE TEST & FOR FUTURE MONITORING.

•

Age 8, earlier the better. Enabling doctors with the information to treat her for all
medical issues is critical

•

4. At age 4 the child's parents could make decisions about possible procedures before
their child begins school.

90

•

10-12 From a developmental viewpoint since it affects the pituitary which can effect
hormone levels etc which may or may not have developmental impact during teenage
years
25+ From insurance perspective - can be difficult to get insurance on own unless part of
a group coverage. Maybe that has changed with new insurance laws

•

With a child that started having trouble at 13 and always feeling that we were "behind
the curve" on dealing with medical issues, I feel anywhere from 8-12 years of age is
appropriate?

•

8-10years old, They can understand it more.

•

If symptoms appear (kidney stones, thyroid, parathyroid, pituitary abnormalities) then I
would encourage earlier gene testing. If symptom free (according to blood work) I
would delay testing until after 18 or 21. Great concern is for health insurance and job
hiring prejudice of having "preexisting condition."
Also of great concern is the psychological effect at any age of having this diagnosis
hanging like a black cloud, if some family member (like my daughter) had severe
consequences- even if they came on after 40.
Important to note:
We did not learn of my husband's MEN1 until we were in our 60's. It would have made
a difference in our family planning if we had learned of this in our 20s.
Thank you. Glad to help in any way we can.
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